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ABSTRACT 
 
Introduction: Systemic sclerosis (SSc) is a complex autoimmune disease characterised by 
autoantibody release, leading to microvascular injury, fibroblast activation and increased 
production of collagen. The genetics of SSc is complex with many genes implicated in the 
development and maintenance of the extracellular matrix (ECM). The main aim of this 
study was to test for differential expression of matrix metalloproteinase 1 (MMP1), tissue 
inhibitor of metalloproteinase 1 (TIMP1) and hepatocyte growth factor (HGF) in SSc 
patients compared to healthy control individuals and to assess whether the differential 
expression of these genes could have an impact on clinical features of the disease.  
 
Methods: Two skin biopsies were analysed for each of 16 black SSc patients, one from 
clinically involved skin (lateral forearm) and one from clinically uninvolved skin (back). 
One skin sample was obtained from 15 ethnically matched control individuals. The 
differential expression of MMP1, TIMP1 and HGF in the clinically involved and uninvolved 
patient samples would be compared to control individuals using relative quantification 
polymerase chain reaction (qPCR). The gene expression profiles were then compared to 
specific clinical features to deduce whether any of the gene expression profiles is 
correlated with the manifestation of specific clinical features.  
 
Results: MMP1 gene expression was significantly decreased in SSc patients for both 
involved (p=0.0004) and uninvolved skin (p=0.0004) compared to controls. Conversely, 
TIMP1 gene expression was significantly increased in SSc patients at both sites compared 
to controls (p=<0.00001 for both comparisons). A trend of significance was observed for 
the difference in TIMP1 expression between the involved an uninvolved skin within the 
patients (p=0.05) with a greater increase in involved skin. HGF had increased gene 
expression in the patients compared to controls for involved and uninvolved skin 
(p=0.002 and 0.004, respectively). The difference in gene expression between the 
involved and uninvolved biopsies was not significant for either MMP1 or HGF (p=0.87 and 
0.83, respectively). The only correlates that may have a biological significance are HGF in 
involved skin correlated with disease activity (r=0.60; p=0.013) and HGF in uninvolved skin 
 vi 
correlated with skin score (MRSS) with r=0.50 and p=0.048. With regards to the 
categorical data, two marginally significant observations were found, once again with 
HGF, which was found to be associated with gender in involved skin (p=0.037) and renal 
disease in uninvolved skin (0.031). 
 
Conclusion: The relative under expression of MMP1 and over expression of TIMP1 reflect 
the pro-fibrotic state of scleroderma skin. The over expression of HGF suggests that HGF 
may play a compensatory anti-fibrotic role, although this is not sufficient to overcome the 
pro-fibrotic state of the skin. This study provides supporting evidence to debunk the myth 
of uninvolved skin in SSc patients. The altered expression of MMP1, TIMP1 and HGF in the 
clinically uninvolved skin of SSc patients suggests that all subcutaneous tissue is affected, 
although to a greater extent in the clinically involved skin of the patients.     
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Chapter 1 
 
Introduction 
 
 
1.1. Definition  
 
Systemic sclerosis or scleroderma (SSc) is an autoimmune systemic rheumatic disease 
characterised by vascular damage, subcutaneous and visceral fibrosis and circulating 
autoantibodies (Vlachoyiannoploulos, 2001). 
 
1.2. History of SSc 
 
Cases of skin diseases that have similar descriptions to SSc can be found in very ancient 
writings, such as that of Hippocrates (460-370 B.C.). It is however, difficult to say whether 
these ancient alludings are truly examples of the disease, as the descriptions were vague 
and inexact (Coyle, 1988). The first modern published account of SSc is generally 
attributed to the Italian, Curzio, in 1753 (reviewed in Roberts-Thomson and Walker, 
2006). The patient was a 17-year-old woman, who was assigned to Dr. Curzio when she 
was admitted to hospital. As described by the doctor, her symptoms were: hardness of 
the skin (differing in degree from place to place), tightness around the mouth, and 
hardness around the neck. Curzio’s student, J.L Alibert, claimed to be the first to 
recognise the disease, calling it “Sclermia Circumscripia” (Coyle, 1988).  
 
There was little mention of the disease in medical literature until 1847, when Dr. Grisoll in 
Paris rediscovered the disease and opened areas of discussion. In 1854 Erasmus Wilson 
described the lesions of one of his patients as “en coup de sabre” or, “the scar of the 
sword wound”. In popular literature during the same century, Sir Arthur Conan Doyle, the 
creator of Sherlock Holmes used SSc as the theme for his book “The Adventure of the 
Blanched Soldier” (Coyle, 1988).   
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By 1900, more than 500 cases of SSc had been reported and discussed in the medical 
literature (Coyle, 1988). The modern “father” of SSc was undoubtedly, Carwille LeRoy, 
who was a prolific figure in the field of rheumatology and was one of the first 
rheumatologists to apply modern scientific methods to study fibroblasts from SSc 
patients. In so doing, he was able to show that these fibroblasts had the ability to 
synthesise and secrete excess collagen in vitro.  He was also among the first to show that 
vascular endothelium is a primary target in SSc (Reviewed by Silver, 2002). 
 
1.3. Epidemiology 
1.3.1. Prevalence 
 
Approximately 75 000 to 100 000 people are affected with SSc in the United States, 
where the disease is found more frequently in African Americans than in Caucasians 
(Bogatkevich et al., 2007). The disease has a female:male ratio of between 3:1 and 8:1 
after child-bearing years and a peak age of 45 to 55 years (Dumith et al., 2007). The 
prevalence of SSc in full-blooded Choctaw Indians from Oklahoma was reported to be at 
least 469/100 000, which is the highest in the world to be reported thus far (Arnett et al., 
1996). These figures compare with an estimated prevalence of SSc in the USA of 26 
cases/100 000 (Herrick and Worthington, 2002). Thai patients have a higher incidence of 
anti-topoisomerase 1 antibodies and are more likely to have diffuse disease compared 
with Australian Caucasians (Chen et al., 2003). African Americans and Hispanics are more 
likely to have diffuse skin involvement and pigment changes than Caucasians, who have 
more facial telangiectasia (visibility of small, dilated blood vessels near the surface of the 
skin) (Chen et al., 2003). The disease has a worldwide distribution and is found to be more 
frequent in females than in males, as much as an 80% higher incidence in females has 
been reported (Selmi et al., 2006). Different populations have been found to have 
differing susceptibility, which can be due to genetic and/or environmental agents. Large 
cohort studies from Australia and the USA have reported that SSc occurred in one or 
more first-degree relatives in 1.4% and 1.6% of the families of patients with SSc. The 
disease is generally considered rare in sub-Saharan Africans (Silman et al., 1996), although 
there is a considerable variation in the prevalence of the disease across the African 
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continent. In 1980, only two cases of SSc were reported in a teaching hospital in Nigeria 
(Somorin and Mordi, 1980) whereas the disease is widely reported in South Africa. The 
incidence of the disease in South African goldminers is approximately 2.5 fold more than 
the general population (7.3-8.1/100 000 vs. 0.33/100 000) (Cowie and Dansey, 1990; 
Tager and Tikly, 1999). 
 
1.3.2. Environmental risk factors 
 
Cases have documented the co-existence of silicosis and progressive SSc in Europe, Japan 
the USA and in Africa (Sluis-Cremer et al., 1985). SSc was uncommon in early studies from 
Africa. Only one case was documented in Nigeria and six in Zimbabwe over a 10-year 
period (Greenwood, 1968; Lutalo, 1985). Erasmus (1957) described the first association 
between gold mining and SSc in South Africa. His study was concerned with the high 
prevalence of progressive SSc in the Johannesburg area where gold miners were exposed 
to dust containing a high percentage (>30%) of free silica.  Subsequent studies in the late 
1980s documented cases of SSc in both white and black gold miners (Cowie, 1987). 
Pudifin et al. (1991) reported the largest series of SSc in Africa, where over 10 years 106 
black and 60 Indian patients were seen. Antinuclear antibodies (ANA) and 
antitopoisomerase antibody (ATA) were more common amongst black patients with 54% 
being ANA positive and 32% being ATA positive.   
 
A disease that appeared in Spain in 1981, affecting approximately 20 000 people, was 
named toxic oil syndrome as it was linked to the consumption of contaminated rapeseed 
oil sold in bulk in the industrial belt of Madrid. Patients presented clinically with edema, 
contractures, Raynaud’s phenomenon and fibrosis of the dermis, suggesting a 
scleroderma-like syndrome (Alonso-Ruiz et al., 1986). In the United States during the 
early 1990s an association was made between ingesting tryptophan and a syndrome 
characterized by scleroderma-like skin abnormalities (fasciitis and eosinophilia), which 
developed within 1 to 18 months after the start of tryptophan therapy for insomnia, 
depression, or obesity. All had histopathological changes in the dermis and subcutaneous 
tissue typical of scleroderma (Silver et al., 1990). 
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1.3.3. Genetic risk factors 
 
The genetics of the disease is complex and there are several lines of evidence that 
support a genetic component to susceptibility to SSc. Twins studies show a low disease 
concordance rate of less than 5% that is similar between mono and dizygotic twin pairs, 
although cases of twins with the disease are extremely rare (Feghali-Bostwick et al., 
2003). Cohort studies, however, suggest that a positive family history is the strongest risk 
factor for SSc identified to date, with an increased relative risk among first-degree 
relatives. It is unclear however, if the increased risk is due to genetic influences or shared 
environmental factors (Chen et al., 2003). Due to the extreme variability of the disease 
phenotypes, epigenetic modifications have been suggested as additional factors, which 
can modify the SSc phenotype (Selmi et al., 2006). Evidence for the role of epigenetic 
modifications in SSc includes studies in which the addition of epigenetic suppressors 
normalised the expression of collagen within SSc fibroblasts (Wang et al., 2006).   
 
Genetic association studies are generally regarded as a useful tool to study the molecular 
aetiology of complex diseases. Complex diseases are likely to be caused by several genes, 
each with a minor contribution to the overall relative risk. It has been proposed that 
combinations of common genetic variants, in particular single nucleotide polymorphisms 
(SNPs), not only influence the susceptibility to complex diseases but also are associated 
with particular aspects of the disease phenotype. The literature is littered with studies 
reporting relationships between various genes and SSc susceptibility or severity. Such 
genes include the HLA and non-HLA genes (Gilchrist et al., 2001; Gladman et al., 2005), 
tumor necrosis factor-α (Sato et al., 2004), endothelin (Fonseca et al., 2006) and fibrillin 
(Tan et al., 2001). All of these studies are able to provide potential insight into the 
pathogenesis and aetiology of the disease. Many studies have shown strong association 
between polymorphisms and the presence of antibodies, which are hallmarks of SSc, such 
as ATA or anti-centromere (ACA) reactivity (Fanning et al., 1998). The information 
generated by genetic association studies could prove to be valuable in diagnosis or 
therapy, but the results have to be interpreted with caution. Most limitations to these 
studies are connected to poor study design and statistical analysis. Underpowered studies 
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are able to provide interesting results, but with no reproducibility. A good example of this 
problem is the results from studies on polymorphisms in the PTPN22 gene in SSc patients 
that cannot be replicated or that are even contradictory (Balada et al., 2006; Gourh et al., 
2006).  
 
1.4. The Clinical Triad 
 
The disease is a multi-system disease, which is highly heterogeneous and has an unknown 
aetiology (Varga and Abraham, 2007). Progression of the disease is known to involve 
three main systems including the immune system, the vasculature system and the 
extracellular matrix (ECM) (Whitfield et al., 2003). Clinically the disease can be separated 
into diffuse cutaneous systemic sclerosis (dcSSc) and limited cutaneous systemic sclerosis 
(lcSSc). The clinical manifestation of each of these sub-groups is widespread skin 
thickening and skin thickening that is limited to the face and distal extremities, 
respectively (Steen, 1998).  
 
The most common manifestations of SSc are the presence of specific autoantibodies with 
more than 90% of patients having antinuclear antibodies in their serum. Anti-
topoisomerase 1 antibodies are almost exclusively present in sera from patients with the 
diffuse form of SSc, with a higher prevalence of these autoantibodies seen in African 
American patients (Maul et al., 1989). Anti-centromere antibodies are more commonly 
present in the sera of patients with the limited form of the disease. These two 
autoantibodies are mutually exclusive, coexisting in the same patient only in rare 
instances. Although autoantibodies are very common in SSc, they are not directly 
involved in the clinical manifestations of the disease and it is generally accepted that their 
titres do not correlate with disease activity or clinical severity (Derk and Jimenez, 2003).  
 
The majority of SSc patients suffer from primary Raynaud’s phenomenon, which is an 
episodic event, characterised by pallor and pain in the peripheries in response to cold 
stress (Young-Min et al., 2001). This symptom is caused by micro-vascular abnormality 
leading to reduced blood flow resulting in digital ulcers and, in some cases, gangrene 
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(Kuwana, 2006). Other symptoms of SSc include muscle weakness (myositis), problems of 
the digestive system and pulmonary arterial hypertension (Clements, 2000).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. Schematic diagram of the SSc clinical triad. 
 
The hallmark symptom of the disease is the gradual thickening and tightening of the skin. 
Often ulcers are found, particularly on the fingertips, which are slow to heal due to poor 
circulation. Other changes in the skin include pigmentation alteration and calcium 
deposits under the skin (Clements, 2000). Fibrosis is especially significant in the diffuse 
form of the disease. Basic remodelling of the ECM occurs causing the architecture of the 
skin to become disrupted and this leads to fibrosis of not only the skin, but also many 
internal organs. The lungs, gastrointestinal tract and heart are the worst affected by the 
fibrotic process. Much morbidity of the disease is due to fibrosis of the internal organs 
(Yazawa et al., 2000).    
 
1.5. Prognosis and Treatment 
 
Clinical outcomes have improved considerably in the last decade, presumably due to 
better management of the complications. The disease is however, still considered 
incurable and the diffuse cutaneous form of the disease carries the highest risk of fatality 
 Vascular  Immune 
 Fibrosis 
Fibroblast 
activation 
 T cell activation 
 Macrophage activation 
 Autoantibodies 
 Cytokines 
 Endothelial cell injury 
 Vasoconstriction 
 Vascular occlusion 
 Tissue hypoxia 
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within the connective tissue diseases, carrying a 55% survival rate at 10 years (Varga and 
Abraham, 2007). Many treatments are being tested for use in SSc patients to alleviate the 
symptoms of the disease. Drugs that are prescribed for treatment of the fibrosis include 
methotrexate, cyclophosphamide and d-penicillamine. Experimental treatments include 
intravenous gamma globulins, collagen tolerance induction and anti-TGF-beta antibodies 
(Bournia et al., 2009).  The immunosuppressive drug, rapamycin, has been found to exert 
an antifibrotic effect, which could be caused by the drug’s ability to directly target ECM 
deposition (Poulalhon et al., 2006). Although these treatments alleviate some of the 
symptoms of the disease, they tend to not be very effective, thus highlighting the need 
for research into an effective therapeutic intervention and on-going clinical, 
pharmaceutical research. To date there is no effective method of treatment for fibrosis. 
 
1.6. Pathogenesis 
 
There has been considerable research toward investigating and elucidating the 
pathogenic processes involved in the development of SSc. Factors affecting susceptibility 
and the initiating event remain largely unknown, however as this is a multifactorial 
disease, there are genetic as well as an environmental components.  The sequence of 
events leading to the development of SSc is illustrated in Figure 1.2.  
 
 
 
Figure 1.2. The sequence of pathological events that lead to the development of SSc (Abraham and Distler, 
2007). 
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1.6.1. Endothelial cells 
 
The endothelium is a highly specialised and complex organ involved in many important 
functions. It enables a compatible interface facilitating blood circulation, inhibits 
excessive platelet aggregation and coordinates vascular tone, which serves to inhibit ECM 
deposition. The endothelium has many prominent endocrine functions, the most 
important of which is the control of inflammation (Abraham and Distler, 2007).  
 
Healthy functioning of the endothelium is crucial for remodeling of blood vessels during 
times of tissue growth and repair. Dysfunction of the endothelium is an important 
component of many common human diseases, including those characterized by 
inflammation and fibrosis (Figure 1.3). Endothelial dysfunction contributes to 
inflammatory and fibrotic connective tissue diseases, particularly SSc and the dysfunction 
that is observed results from endothelial cell injury leading to the generation of an 
inflammatory process and endothelial cell activation (Ross, 1999). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3. The many mechanisms of endothelial dysfunction, all of which are evident as symptoms in 
systemic sclerosis (Abraham and Distler, 2007). 
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1.6.2. Immunocytes (T-cells) 
 
Immunocytes, or T cells, play a pivotal role in SSc although their precise role has not 
been fully elucidated. It is likely that T cell-derived cytokines contribute to the 
development of fibrosis. A study by Fuschiotti et al. (2009) focused on the ability of CD4+ 
and CD8+ T cells to produce cytokines following in vitro activation. They concluded that 
dysregulation of IL-13 production by CD8+ T cells is important in the pathogenesis of SSc 
and appears to be critical in the predisposition to more severe forms of cutaneous 
disease. Abnormalities in the cellular immunity of SSc patients consist of chronic 
mononuclear cell infiltration of tissues and the dysregulation of lymphocytes, growth 
factor and the production of autoantibodies. The expansion and activation of CD4+T 
cells as an early immune event is considered important in the development and 
maintenance of SSc (Besliu et al., 2009). T cells in the skin exhibiting high interleukin-4 
(IL-4) production and T cells in the blood that express chemokine receptors associated 
with TH2 functions are found in SSc patients with active disease. Dermal fibrosis and 
capillary loss typical of systemic sclerosis can be reversible after high-dose immuno-
suppression and haematopoietic stem cell transplantation (Chizzolini, 2008). 
 
1.6.3. Fibroblasts 
 
Fibroblasts play an important role in the metabolism of the ECM connective tissues within 
the skin. Fibrosis of the skin is due to an increase in the deposition of the ECM, including 
microfibrils and collagens (Lemaire et al., 2006). The ECM functions as a reservoir for 
many growth factors including TGFβ, CTGF and a number of other multicellular proteins. 
Excessive connective tissue accumulation is due to an overproduction by fibroblasts, 
which are activated by cell-cell or cell-ECM interactions. Collagens are by far the most 
abundant ECM components and have crucial roles in organ development, growth and 
differentiation. The collagen genes have been studied extensively and have been found to 
harbour highly conserved regulatory regions that are recognised specifically by DNA-
binding transcription factors. Any alterations that occur in these interactions will 
contribute towards persistent fibroblast activation in systemic sclerosis (Varga and 
Abraham, 2007). 
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Figure 1.4. Vascular and immunological processes leading to fibrosis in SSc (Varga and Abraham, 2007). 
 
There are many molecular effectors and determinants of fibrosis, the master regulator of 
these is considered to be TGFβ (Ihn, 2002). This gene is considered a potent pro-fibrotic 
stimulus and regulates cell growth, death, differentiation and synthesis of the ECM (Ihn, 
2008). An increase in the number of TGFβ receptors has also been linked to the 
development of fibrosis (Yamane et al., 2002) although fibroblasts from SSc patients have 
been found to produce TGFβ at levels equivalent to that of normal fibroblast cells 
(Needleman et al., 1990).  
 
CTGF (connective tissue growth factor) functions as an adaptor molecule that connects 
cell surfaces to the ECM. The gene encoding CTGF is expressed in relatively low levels in 
the tissue of normal individuals whilst showing markedly increased expression in SSc 
patients and in animal models such as the tight skin (Tsk) mouse (Ihn, 2002). CTGF over 
expression is considered a molecular marker of fibrosis. Hepatocyte growth factor (HGF) 
has been found to attenuate CTGF expression and collagen accumulation in mouse 
models with fibrosis (Bogatkevich et al., 2007).  
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1.7. Mediators of collagen metabolism 
 
Collagen is the most abundant proteins on earth and accounts for 30% of the total protein 
in the human body. Collagen provides normal tissue with strength, integrity and structure 
and when tissue is injured, collagen repairs and restores structure and thus function. Too 
much collagen at a wound results in fibrosis and conversely, if insufficient amounts of 
collagen are deposited, the wound is weak and may rupture (Burgeson, 1987). Pivotal in 
the turnover of the ECM is the matrix metalloproteinase (MMP) family who have the 
ability to degrade not only collagen, but also most proteins that constitute the ECM. 
Conversely, the tissue inhibitors of metalloproteinases (TIMPs) protect the integrity of the 
ECM by inhibiting MMP activity (Hall et al., 2003). Hepatocyte growth factor is known to 
have anti-fibrotic properties and its ability to break down collagen has been reported in 
many studies (Bogatkevich et al., 2007; Esposito et al., 2009). Figure 1.5 illustrates the 
effect of growth factors (TGFβ and CTGF), matrix metalloproteinases, tissue inhibitors of 
metalloproteinase and hepatocyte growth factor on collagen metabolism, and 
consequently fibrosis and their role in ECM synthesis or degradation. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5 Diagrammatic representations of the key modulators of fibrosis in SSc.  
 
  ↑TIMP1 
           Pro-fibrotic = ↑ Collagen 
Collagen 
   Anti-fibrotic = ↓ Collagen 
  ↓MMP1 
    ↑HGF 
  ↑TGFβ 
  ↑CTGF 
  ↓TIMP1 
  ↑MMP1 
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1.7.1. Matrix metalloproteinase 1 
 
The first of the metalloproteinases (MMPs), interstitial collagenase 1 (MMP1), was 
discovered by Gross and Lapiere in 1962 in the tail of a tadpole. The MMPs are all 
involved in normal tissue remodelling processes, such as embryonic development, 
postpartum involution of the uterus, ovulation and wound healing as well as in important 
disease processes such as joint destruction in rheumatoid arthritis (RA) (Curry et al., 2003; 
Salmela et al., 2004; Woessner, 1991; Pap et al., 2005). The accumulation of ECM is 
dependent on the balance between the synthesis and degradation of the 
metalloproteinases (Matilla et al., 1998).      
 
The chief characteristics of genes of the metalloproteinase family are, their dependency 
on zinc for their activation, the cDNA sequences all show homology to that of collagenase, 
the enzymes cleave one or more components of the extracellular matrix and finally, the 
activity of the proteinases is inhibited by one of the tissue inhibitors of 
metalloproteinases (TIMPs) (Toubi et al., 2002). MMP1 is by far the most widely studied 
metalloproteinase and was found to degrade fibrillar collagen at a neutral pH (Young-Min 
et al., 2001).  
 
In SSc, as in other rheumatic diseases such as RA and systemic lupus erythematosus (SLE), 
certain cells including fibroblasts are exposed to pro-inflammatory cytokines. These 
cytokines, IL-1, IL-6 and TNFβ, are responsible for the resultant overproduction of MMPs 
(Toubi et al., 2002). Antibodies specific to both MMP1 and MMP3 have been reported 
specifically in the serum of SSc patients (Arnett, 2006). These antibodies have been 
proposed to result in a failure to degrade ECM components that cause accumulation of 
fibrotic material (Arnett, 2006).  
 
1.7.2. Tissue inhibitor of metalloproteinase 1 
 
Tissue inhibitors of metalloproteinases (TIMPs) are secreted from fibroblasts and act 
locally to specifically block the active MMPs and prevent matrix digestion. Four TIMPs 
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have been described to date of which TIMP1 and TIMP2 are the most widely studied and 
are produced in soluble forms. The expression of TIMP1 is also differentially regulated 
and production of the gene product is enhanced by growth factors, especially TGFβ 
(Matilla et al., 1998).    
 
Many previous in-vitro studies have shown that skin fibroblasts from SSc patients produce 
elevated amounts of TIMP1 when compared to control samples (Matilla et al., 1998). 
TIMP1 also appears to be increased in serum levels of SSc patients who have active 
disease (Kikuchi et al., 1995). This brings to the fore that it is the balance between matrix  
degrading enzymes and their inhibitors that contribute to the development and 
pathogenesis of fibrosis in SSc (Toubi et al., 2002). A study by Susol et al. (2000) indicates 
that increased expression of TIMP1 may be a susceptibility marker in males who develop 
SSc. There was a lack of association with the TIMP1 marker and female SSc patients, 
which may indicate that the aetiology of the disease is different in males and females 
(Susol et al., 2000). Systemic sclerosis cell lines have been found to synthesize elevated 
levels of TIMP1 and these high levels could play an important role in the fibrotic process 
by inhibiting collagen degradation (Kirk et al., 1995).   
 
In a study conducted by Kikuchi et al. (1995) an increased level of TIMP1 in serum was 
correlated with an increased incidence of lung fibrosis. It has also been suggested that the 
TIMP1 level reflects the severity of the disease in patients with SSc. Fibroblasts from SSc 
patients have shown decreases in collagenase activity and production, with no observable 
differences seen in the levels of collagenase mRNA, which suggests that collagenase is 
altered at the level of translation (Takeda et al., 1994).  
 
1.7.3. Interaction between MMP1 and TIMP1 
 
TIMPs form very tight complexes in a 1:1 ratio with the MMPs (figure 1.6), although with 
some low selectivity, for example TIMP1 does not always have to bind to MMP1, it can 
bind to many of the other MMP molecules. Mutational analysis has shown that changes 
made to the interaction site of the TIMPs can drastically change the affinity for different 
MMPs (Iyer et al., 2007). Investigating the roles of MMP1 in physiological processes could 
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form part of a potential route for new therapies in diseases that are associated with 
excess MMP activity (Iyer et al., 2007).          
  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6. Ribbon three-dimensional structure of the N-terminal domain of TIMP1 (green) in 
complex with the catalytic domain of MMP1 (pink) (Iyer et al., 2007).  
 
 
1.7.4. Hepatocyte growth factor 
 
Hepatocyte growth factor (HGF), a potent mitogen also known as “scatter factor”, shows 
mitogenic and morphogenetic properties in a variety of cells (Jinnin et al., 2005) and is 
involved in tissue regeneration after organ injury (Bogatkevich et al., 2007). Much 
evidence has accumulated which indicates that HGF has an important role in vivo as a 
hepatotrophic factor during regeneration of livers that have been injured by hepatectomy 
or hepatotoxin treatment (Kawaguchi et al., 2002). HGF targets many cell varieties 
including mesenchymal cells such as fibroblasts and renal epithelial cells.  The many 
regulating effects of the gene product include cell proliferation, migration, 
morphogenesis, development and regeneration (Kawaguchi et al., 2002).  
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HGF has recently been shown to reverse the process of fibrosis by successfully inhibiting 
ECM deposition and reducing the amount of fibrillar collagen (Motone et al., 2004). This 
function of HGF has been studied extensively in an animal model but its effects in humans 
are not fully understood. One of the anti-fibrotic mechanisms of HGF however involves 
the induction of MMP1 expression. The effects of HGF in SSc fibroblasts have not been 
studied extensively and in one study the investigators were interested in the direct effect 
of HGF on the expression of type 1 collagen (Jinnin et al., 2005). The study found that HGF 
functions like a cytokine that mediates tissue remodelling in the liver and skin. The study 
concluded that HGF has a direct effect on the deposition of collagen in fibrotic conditions 
(Jinnin et al., 2005).  
 
Bogatkevich et al., (2007) undertook a study, which compared cytokine composition in 
bronchoalveolar lavage (BAL) samples in African Americans and Caucasians with SSc. They 
observed that HGF was the only cytokine that caused lower collagen expression in the 
lung samples. Further study showed that HGF was diminished in the lung fibroblasts 
isolated from the African American patients only, due to limitations in c-Met receptor 
phosphorylation.      
 
1.8. Methods for studying gene expression 
 
There is an array of methods that can be used for studying the expression of genes, each 
with advantages and disadvantages. Although relative quantitative polymerase chain 
reaction (qPCR) was the method of choice for this study, this and a few other methods 
are addressed along with some advantages and disadvantages.    
 
Using reporter genes such as green fluorescent protein (GFP) can reveal where and when 
a gene is expressed. The expression of a gene is controlled by regulatory sequences, 
which can be manipulated to drive the expression of a reporter gene, by replacing the 
target gene’s coding region with the reporter gene. The level, timing, and cell specificity 
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of reporter protein production reflect the action of the regulatory sequences that belong 
to the original gene (Chalfie et al., 1994). 
 
Northern blotting allows the detection of low-resolution expression patterns by 
hybridising a gene or cDNA probe to total RNA or poly (A)+ RNA extracts prepared from 
different tissues or cell lines. Because the RNA is size-fractionated on a gel, it is possible to 
estimate the size of transcripts (Alwine et al., 1977).  
 
In situ hybridisation (ISH) is a technique that enables the morphological demonstration of 
specific DNA or RNA sequences in specific cells or tissues. It is the only method that allows 
for the identification of specific DNA/RNA sequences in a heterogeneous cell population, 
and thereby provides information on whether a gene is expressed in low or high levels in 
the cells. When this technique was introduced in 1969, it was developed for the easy 
localisation of DNA sequences, since then it has also been applied to viral DNA, mRNA and 
entire chromosomal regions (Simmons et al., 1989).    
 
Immunohistochemistry is a technique that localises proteins in tissue sections by 
exploiting the principle of antibodies binding to antigens in biological tissues. Since 
immunohistochemistry involves specific antigen-antibody reaction, it has apparent 
advantage over traditionally used special enzyme staining techniques that identify only a 
limited number of proteins, enzymes and tissue structures (Ramos-Vara, 2005). 
 
Serial analysis of gene expression (SAGE) is a method for multiplex gene expression 
screening which uses short sequence tags, which are located within transcripts.  SAGE is 
one of the most accessible methods for studying gene expression, as it does not require 
sophisticated equipment to track gene expression. SAGE provides a measure of transcript 
quantification since genes that are highly expressed in a specific tissue will frequently be 
recovered as sequence tags. An advantage of the method is its speed (Velculescu et al., 
1995).  
 17 
 
In recent years, studying gene expression by conventional real time PCR (qPCR) has 
become the standard technique for various reasons. The advantage of PCR-based 
methods for studying gene expression is the speed, sensitivity and simplicity of the 
technique as well as providing a rough quantification of the expression of a particular 
gene. The sensitivity of PCR means that this method can also be used to study expression 
in single cells. In addition, qPCR can be useful for identifying and studying the expression 
of different isoforms of an RNA transcript (Heid et al., 1996). 
 
Developed in the 1990s, DNA microarrays have revolutionized the way in which gene 
expression is analysed by allowing the RNA products of thousands of genes to be 
monitored at once. The ratio of two different fluorochromes reflects the relative 
expression of the genes on the slide. DNA chip technology has revolutionised the study of 
gene expression and has become standard practise in many gene expression studies but 
the most challenging part of any microarray experiment is the analysis of the data that is 
produced (Schena et al., 1995). 
  
1.9. Microarray studies for gene expression in SSc 
 
Studies that have analysed the gene expression in SSc fibroblasts using microarray, 
although few, have shown that there are consistent differences in the gene expression 
patterns between tissue samples from controls and patients. These differences were even 
detected in skin that was not clinically affected at the time the biopsy was taken 
(Whitfield et al., 2003). In this same study DNA microarray showed that TIMP1 is up 
regulated in patients with SSc compared to control individuals. This up regulation was up 
to eight times higher in some patients.    
 
In another study by Milano et al. (2008) it was found that gene expression profiling on a 
genome-wide basis demonstrated that the heterogeneity of SSc can be quantitatively 
measured using DNA microarrays. Such diverse gene expression shows that there are 
multiple and distinct gene expression profiles specific to the skin of SSc patients. But the 
interesting and perhaps most important finding in this study was that the gene expression 
 18 
 
data shows that there are at least two very distinct patient sub-groups within patients 
with the diffuse disease. The authors also report on a 177-gene signature that is 
associated with the severity of the skin in the diffuse disease.  
 
1.10. Factors controlling the expression of genes 
 
Aberrant gene expression could be caused by a number of different mechanisms, each 
one unique and exerting it’s affect in a different manner. The change observed in the 
patients with respect to the expression of particular genes could be caused by 
polymorphisms in the promoter sequences of the genes, epigenetic modification, 
abundance of transcription factors, hormones, other physiological differences between 
males and females as well as medication. 
 
1.10.1. Polymorphisms 
 
There are currently few candidate gene single nucleotide polymorphism (SNP) association 
studies for SSc, and in these the investigators use small sample sizes and the 
reproducibility of the results is low. Interestingly, several studies have implicated 
promoter polymorphisms suggesting that these may affect gene expression. Some 
examples of SNP associations found in SSc include TNFα polymorphisms –238A and 
+489A, and a MCP1 promoter polymorphism,  –2518 (G/G genotype is associated with 
SSc) (Assasi and Tan, 2005).    
 
A SNP in MMP1, where a G is inserted into the promoter region was found to up regulate 
the transcription of this gene by creating a transcription factor binding site. This increases 
the transcription of the gene, resulting in irreversible degradation of collagen (Rutter et 
al., 1998). In a study by Indelicato et al. (2006) three polymorphisms were analysed in 
TIMP1 (-19A>G, +261C>T and +372T>C). They found that the C allele of the +372T>C 
polymorphism was observed in higher frequencies in male SSc patients than controls 
while there was no difference in the frequency of the allele between female SSc patients 
and controls. They suggested that this polymorphism might predispose men to SSc. Three 
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SNPs within HGF,  -1652C>T in the promoter region, +44222C>T in intron 9, +63555G>T in 
exon 15 were genotyped in SSc patients. The +63555 T/T genotype was correlated with 
marginally decreased gene expression in SSc patients, compared with healthy controls 
(p=0.02). Of 141 SSc patients whose disease duration was > 10 years, 17 (12%) developed 
lung disease, which was found to be more prevalent in patients with the –1652 T/T 
genotype than in those without (p=0.002). It was concluded that these SNPs in HGF could 
be used to predict lung disease in SSc patients (Hoshino et al., 2008). Further analysis of 
these genes, as a whole, need to be done in order to deduce if functional polymorphisms 
contribute as causative agents in the development of the disease. Most recently 
polymorphisms have been found in the IRF5 region (Ito et al., 2009) and the hypoxia-
inducible factor 1A (HIF1A) gene (Wipff et al., 2009). These polymorphisms are associated 
with SSc in patients of Japanese and European ancestry respectively.  
 
1.10.2. Epigenetic Modifications 
 
Epigenetics refers to the heritable changes in gene expression that do not involve changes 
to the DNA sequence. The epigenetic regulation of gene expression is a dynamic process 
that plays a pivotal role in normal cell growth and differentiation (Strietholt et al., 2008). 
There are three main epigenetic mechanisms, DNA methylation, histone modification and 
RNA interference (RNAi) (Cheng et al., 2008). 
 
DNA is highly organised within the chromatin. Euchromatin is uncondensed and 
transcriptionally active whereas heterochromatin is condensed and transcriptionally 
inactive rendering the genes in that area silenced. In order to achieve these states of 
transcriptional activity, the chromatin is dynamically modified by either histone 
acetyltransferases (HATs) or histone deacetylases (HDACs). HATs catalyse histone 
acetylation and this hyperacetylation of the N-terminus of the histones is associated with 
the opening of the chromatin and thus enhancing the rate of gene transcription and 
therefore expression (de Ruijter et al., 2003). On the other hand, HDACs remove the 
acetyl group from the histones resulting in hypoacetylation, reducing the space between 
the chromatin and the DNA. This hinders transcription factors from binding to the DNA, 
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leading to the silencing of affected genes (Briggs et al., 2002).  HDAC inhibitors have been 
found to be therapeutically beneficial in certain cancers (Kim et al., 2006) as well as 
animals models of autoimmune diseases such as multiple sclerosis (Gray and Dangold, 
2006) and SLE (Mishra et al., 2003).  In SSc, the knockdown of HDAC7 in skin fibroblasts 
and treatment of skin fibrosis in mice with the HDAC inhibitor “trichostatin A” have both 
been shown to markedly reduce the accumulation of ECM protein and therefore the 
development of fibrosis (Nasu et al., 2008). 
 
DNA methylation involves the methylation of deoxycytosine bases in CG dinucleotide 
pairs often within CpG islands and as this is the major form of modifying eukaryotic DNA, 
it has a profound effect on gene expression. DNA methylation is responsible for inhibiting 
gene expression and does so in several ways (Li et al., 2009). Methylation of promoter 
sequences inhibits the ability of certain transcription factors binding to the DNA. Several 
DNA methyltransferases (Dnmt) are responsible for catalysing the methylation process, of 
which Dnmt1 is the most abundant. Insertion of a methyl group into DNA by a Dnmt 
results in changes in chromatin structure and thus silencing of an affected gene. 
Methyltransferases are also susceptible to inhibition by chemicals and are sensitive to 
environmental influences which both have an effect on gene expression patterns 
(Richardson, 2008). Recently, mutations in Dnmt3 have been found to cause 
abnormalities in the immune system (Richardson, 2008). The role of DNA methylation in 
regulating retroviral elements responsible for the reactivation of suppressed sequences 
could contribute to autoimmunity (Richardson, 2008).  
  
Recently, a new class of post-transcriptional regulators has emerged. These are small, 
endogenous, single-stranded, non-coding RNAs called micro RNAs (miRNAs). These have 
been estimated to account for between 2% and 3% of the human genome and regulate 
approximately 30% of human genes (Lewis et al., 2003). There is rapidly increasing 
evidence that miRNAs are involved in many physiological and pathological processes, 
including an important role in immune responses and the development of autoimmunity 
(Cobb et al., 2006; Rodriguez et al., 2007; Li et al., 2007; Pauley et al., 2009). Recent 
studies have found that altered expression and function of miRNAs could be involved in 
the pathogenesis of rheumatoid arthritis (RA) (Stranczyk et al., 2008) and SLE (Dai et al., 
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2007). In RA patient samples it was found that miR-155 expression was higher than in 
control samples and it is suggested that a possible target of this miRNA is matrix 
metalloproteinase 3 (MMP3). This may be a mechanism to modulate downstream tissue 
damage. Figure 4.1 is a summary of the consequences of irregular miRNA regulation in 
immune functions.  
 
The detailed role of miRNA regulation and dysregulation in autoimmune diseases still 
needs to be elucidated. However, miRNAs are emerging as a potential target for new 
therapies in the treatment and prevention of autoimmunity.  
 
 
 
 
 
 
 
 
 
 
Figure 1.7. Consequences of abnormal miRNA regulation in autoimmunity (Pauley et al., 2009) 
 
 
1.11. Study Aim and objectives 
 
The predicted outcome of the study is that both TIMP1 and HGF will have higher 
expression levels in the clinically involved SSc skin compared to both the control and 
clinically uninvolved SSc skin. Conversely, MMP1 is expected to have lower expression in 
the clinically involved SSc skin compared to the control and clinically uninvolved SSc skin. 
The clinically uninvolved skin from the SSc patients is expected to have similar expression 
levels for MMP1, TIMP1 and HGF to the control skin.  
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The aim of this study was to test for differential expression of MMP1, TIMP1 and HGF in 
SSc patients compared to healthy individuals and to determine if expression profiles 
correlated with clinical features. There were three objectives to achieve this aim. 
 
Objective 1: To elucidate the gene expression profiles of MMP1, TIMP1 and HGF in skin 
biopsy samples from SSc patients and healthy controls using quantitative real time PCR 
(qPCR).  
 
Objective 2: To elucidate the gene expression profiles of MMP1, TIMP1 and HGF in 
clinically involved SSc skin compared to clinically uninvolved SSc skin using quantitative 
real time PCR (qPCR). This objective will refute or support the myth of uninvolved skin in 
SSc patients.  
 
Objective 3: To correlate the gene expression profiles of the patients with clinical features 
of the disease.  
 
Ethics clearance for collection and use of these biological samples was obtained from the 
Human Research Ethics Committee (Medical) of the University, ethics approval number 
M070820 (Appendix A). 
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Chapter 2 
Subjects and Methods 
 
2.1. Subjects 
2.1.1. Patients 
 
Consenting black South African patients from Chris Hani Baragwanath Hospital who 
fulfilled the 1980 American College of Rheumatology (ACR) preliminary criteria for 
classification of Scleroderma (Masi et al., 1980), had diffuse cutaneous disease (Leroy et 
al., 1988) and who had less than 6 years disease duration were included in the study. 
Originally 17 patients were recruited but one was excluded due to long disease duration 
and thus only 16 patients were used in the study. 
 
Clinical and laboratory features that were documented at the time of taking biopsy 
samples were: 
 
1. Modified Rodnan skin score: 
Bedside clinical assessment of subcutaneous skin thickening based on a scale from 0 
(normal) to 3+ (severe) at 17 anatomic areas; the maximum score is 51 (Furst et al., 1998). 
The assessment was done by a single trained medical professional to avoid inter-observer 
variability.   
2. Interstitial lung disease: 
Bilateral respiratory fine crackles, radiograph revealing reduced lung volume and 
bilateral, reticulonodular opacities. FEV1 (forced expiratory volume in one second) and 
FVC (forced vital capacity) both diminished (Harrison et al., 1991). 
3. Pulmonary hypertension: 
Right systolic ventricular pressure of >40mmHg on echocardiogram (Gaine and Rubin, 
1998). 
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4. Renal involvement: 
Proteinuria levels at +1 protein or more on a urine dipstick. Renal dysfunction is indicated 
by serum urea levels of >8mmol/L and/or creatinine levels of >100mmol/L. 
5. Myositis: 
Symmetrical proximal muscle weakness with at least 2 of the following three features: 1) 
typical electromyelogram changes, 2) raised creatine kinase, 3) muscle degeneration or 
necrosis  (Bohan and Peter, 1975). 
6. C-reactive protein: 
The CRP test indicates acute inflammation by assessing the amount of the protein in 
blood (normal range between 1.0 and 3.0 mg/L, high >10 mg/L). To perform the test, 
patient serum is added to a CRP/latex solution onto a glass slide. Positive and negative 
controls should be done simultaneously. After slight agitation the results are read under 
an indirect oblique light source. A positive reaction is indicated by agglutination. 
7. Erythrocyte sedimentation rate: 
The ESR test is a measure of the settling of red blood cells per hour. This rate is an 
indication of inflammation (High >30mm/hour). To perform the test, 
anticoagulated blood is placed in an upright Westergren tube, and the rate at 
which the red blood cells fall is measured and reported in mm/h. Although, since 
the introduction of automated analysers into the laboratory, the ESR test has been 
automatically performed. 
8. Serum C4: 
Serum levels of C3 and C4 are determined antigenically by a turbidimetric procedure. 
Turbidity testing determines the cloudiness of a solution and measuring the loss of 
intensity of a light beam that passes through that solution. Levels of between 0.2 and 1.0 
are considered low.  
9. Global disease activity: 
This is calculated using scores that are assigned to certain parameters (MRSS, scleredema, 
skin, digital necrosis, vascular, arthritis, DLCO, ESR>30mm/hour, hypocomplementemia) 
with maximum scores of individual parameters ranging from 0.5 to 2 giving a maximum 
total of 10. The disease is considered active if the score is equal to or greater than 3 
(Valentini et al., 2001). 
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2.1.2. Controls 
 
Control samples were obtained from fifteen consenting (Appendix B), otherwise healthy 
individuals undergoing reconstructive plastic surgery at the Charlotte Maxeke 
Johannesburg Academic Hospital.  
 
2.2. Laboratory Methods 
2.2.1. Collection and transportation of samples 
 
Two 4mm punch skin biopsies were taken from each patient. A biopsy for clinically 
involved skin was taken 4cm proximal to the ulna styloid (Whitfield et al., 2003) on the 
dorsum of the left forearm and the biopsy for clinically uninvolved skin was taken from 
the upper back. Skin samples from control individuals were collected from the forearm 
area, except from one individual where it was taken from the groin. The skin samples for 
both patients and controls were placed in a cryotube and immediately immersed in liquid 
nitrogen so that the sample is flash frozen to ensure that no RNA degradation occurs.  
 
2.2.2. RNA extraction 
 
RNA was extracted from skin biopsies that had been flash frozen in liquid nitrogen within 
a few days of collection using the commercially available RNeasy Micro Plus kit (Qiagen) 
(Appendix C). The tissue sample was cut in half and approximately 1-2mg of the tissue 
sample was used for RNA extraction. The RNA was quantified on the Nanodrop 
spectrometer, showing that the average yield was 1μg of total RNA. Purity of RNA isolated 
with RNeasy Kits was evaluated by determining the ratio of absorbance readings at 260 
nm and 280 nm (A260/A280). This ratio provides an estimate of the purity of RNA with 
respect to contaminants that absorb in the UV range, such as protein. Pure RNA has an 
A260/A280 ratio of 1.8-2.1, the RNA isolated in this study averaged a ratio of 1.8 , which is 
considered pure enough to continue with qPCR experiments (Wilfinger et al., 1997). 
 26 
 
The RNA was used directly for reverse transcription polymerase chain reaction (rt-PCR). 
All the RNA samples were stored at -70C. These samples were found to be stable for up 
to one year. 
 
2.2.3. Reverse transcription polymerase chain reaction (RT-PCR) 
 
According to nomenclature published in the MIQE (minimum information for publication 
of quantitative real-time PCR experiments) (Bustin et al., 2009), reverse transcription PCR 
is abbreviated to RT-PCR, qPCR refers to quantitative real-time PCR and Cq should be 
used as to describe the fractional PCR cycle used for quantification as CT and CP becomes 
confusing. The MIQE abbreviations will be used throughout this dissertation. 
   
Total RNA extracted from the skin samples was reverse transcribed into cDNA using the 
ImProm-II Reverse Transcription kit (Promega). This kit uses an oligo (dT) reverse 
transcription primer, which will bind to the poly-A tails of the mRNA fragments. All the 
reagents and enzymes within the kit were extremely temperature sensitive and thus had 
to be thawed on ice. Incubation steps in this protocol had to be performed using a 
heating block or a PCR machine without a heated lid. It is important to note that both a 
no-template control (NTC) as well as a no-amplification control (NAC) was used during 
reverse transcription runs. An NTC should be run to rule out cross contamination of 
reagents and surfaces. This control includes all of the RT-PCR reagents except the RNA 
template, substituted for with nuclease-free water. No product should be synthesised, if a 
product is amplified it is an indication that one or more of the RT-PCR reagents is 
contaminated with the amplicon. The NAC is a minus-reverse transcriptase control, which 
contains all the RT-PCR reagents, including RNA, except the reverse transcriptase. If a 
product is seen in the NAC, it probably indicates that contaminating cDNA is present in 
the sample. 
 
Firstly, 4μl target RNA was added to 1μl of 0.5μg/μl Oligo (dT) primer and incubated at 
70°C for five minutes. The samples were then centrifuged, during which time the other 
reagents were combined in the amounts given in Table 2.1. The reagents were then 
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added to the RNA/primer mix. The PCR conditions using a GeneAmp 2720 Thermal cycler 
are: anneal at 25°C for five minutes, extend at 45°C for 1.5 hours and inactivate at 70°C 
for 15 minutes. The cDNA samples were then quantified using the Nanodrop ND1000 
spectrophotometer. The cDNA could be stored at 4°C until required.    
 
Table 2.1. Standard reverse transcription PCR mixture 
Component Concentration Amount (μl) 
Nuclease-free ddH20  3.7μl 
ImProm-II buffer 5x 4μl 
MgCl2 25nM 4.8μl 
dNTP Mix  10mM 1μl 
RNAse inhibitor  40U/μl 0.5μl 
ImProm-II Reverse Transcriptase enzyme  1μl 
TOTAL  15μl 
 
 
2.2.4. Primer design 
 
Gene specific primers and total cDNA were used for qPCR (Appendix D). Primer pairs were 
designed so that they contained sequences from two adjacent exons ensuring that 
amplification of genomic DNA is reduced. The primers were then aligned against human 
cDNA reference sequences using the nucleotide BLAST algorithm in NCBI 
(http://www.ncbi.nlm.nih.gov). The primer sequences and annealing temperatures are 
listed in Table 2.2.  The sequences of the primers for the reference gene, GAPDH, were 
found in the literature (Kapadia et al., 2003). All primers were purchased from Whitehead 
Scientific, manufactured by IDT (San Diego, United States of America).  
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Table 2.2. Primer sequences to amplify cDNA samples using Real Time PCR 
Gene Sequence (5’  3’) Annealing  
temp (˚C) 
Product 
size (bp) 
Changes to 
protocol 
MMP1 (F) GAGCAAACACATCTGAGGTACAGGA 52 185 None 
MMP1 (R) TTGTCCCGATGATCTCCCCTGACA 
TIMP1 (F) CCGACCTCGTCATCAGGGCCAAG 56 103 Added 4μl 
Betaine to 
each sample 
TIMP1 (R) AACCCTTTATACATCTTGGTCA 
HGF (F) GAAGCTTGCCAGGCCTGCTGTC 57 135 Added 1μl 
primer 
HGF (R) CCATCATAGTTGATCAATCCAG 
GAPDH (F) GAAGGTGAAGGTCGGAGTC 52, 56, 57 210 None 
GAPDH (R) GAAGATGGTGATGGGATTTC 
 
2.2.5. Quantitative real time PCR (qPCR) 
 
Optimisation of any qPCR assay is key to its success and to ensure increased sensitivity, 
specificity and reproducibility (Appendix E). Primer concentrations in the reaction mix 
must be optimised to improve the assay sensitivity (Nolan et al., 2006). The use of melting 
curves when optimising is a powerful tool that provides accurate identification of 
amplified products and distinguishing them from primer dimers, as the short primer 
dimers will melt at lower temperatures. Lastly, the addition of PCR enhancers, such as 
DMSO or Betaine, has been known to greatly improve a real time assay. To optimise the 
qPCR assays in this study each of the above mentioned variables, as well as altering the 
number of PCR cycles during the qPCR run, were optimised to improve PCR sensitivity. 
 
The Roche LightCycler® 2.0 was used for the gene expression analysis. The assays were 
set up using the standard protocol for qPCR with slight modifications for each gene (Table 
2.3). Preparation was done in a pre-PCR room, where no PCR products are allowed, to 
ensure minimal risk of contamination. Before starting PCR set-up, an enzyme was added 
to the SYBR Green DNA 1 (Roche) Master Mix Tube as per the supplier’s 
recommendations. This mixture had to be handled in a way that avoided light and heat 
exposure. The PCR mix was then placed in the well of the capillary tubes followed by the 
cDNA, the capillaries were then centrifuged and placed in the LightCycler®. Water blanks 
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were added as negative controls during the q-PCR runs. The standard assay protocol is 
shown in Table 2.4. 
 
Table 2.3. Standard qPCR mix when using the Roche LightCycler® 2.0 using the Roche SYBR Green DNA 1 kit 
Component Concentration  Amount 
cDNA 500ng/µl 2µl 
ddH20  14µl 
SYBR Green Master Mix 10x 2µl 
Forward Primer 10µM 1µl 
Reverse Primer 10µM 1µl 
TOTAL  20µl 
 
Table 2.4. Standard qPCR assay protocol for the Roche LightCycler® 2.0 
Program Analysis mode 
Temperature 
and duration Slope 
Acquisition 
mode 
Hot Start  
(1 cycle) 
None 95°C  10 mins  20 None 
PCR  
(45 cycles) 
Quantification 95°C  10 secs 20 None 
 Annealing temp 
 10 secs 
20 None 
72°C  10 secs 20 Single 
Melting Curve  
(1 cycle) 
Melting curve 95°C  0 secs 0 None 
 65°C  1 min 20 None 
95°C   0 secs 0.1 Continuous 
Cool  
(1 cycle) 
None 40°C  30 secs 20 None 
 
 
After each qPCR run the products were run on a 3% agarose gel in order to ensure that 
the product being amplified was the correct size and that there were no spurious bands 
being amplified.  
 
Relative qPCR measures the level of expression of a candidate or target gene to a 
reference gene, normally a ubiquitously expressed housekeeping gene. In this study the 
reference gene chosen was glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) as this 
gene has been used as the endogenous control for many other SSc gene expression 
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studies (Renzoni et al., 2004; Nishijima et al., 2004; Wang et al., 2006; Milano et al., 
2008). The results obtained from relative qPCR are measured as a Target gene/Reference 
gene ratio, which is calculated by the software (version 4.05) on the LightCycler® 2.0 
instrument using the differences between the threshold crossing-points (Cq) of the 
samples. Three replicates were done per patient and control sample for each gene. 
Triplicate runs are the gold standard as this allows the investigator to check the 
reproducibility of the assay and the validity of the results obtained (Ahmed, 2002).  
 
2.2.6.  Analysis of qPCR 
 
Analysis was based on the assumption that the concentration of DNA at a sample’s 
crossing point (Cq) was the same for every sample containing the same target DNA. The 
Cq is the DNA concentration necessary for the LightCycler® fluorimeter to detect a signal. 
It is important that a Cq value differ by no more the 0.5 for any sample (Ahmed, 2002). To 
mathematically assess the reproducibility of the Cq values of the assay, the coefficient of 
variation (CV) was calculated. In order to calculate this value, the mean and the standard 
deviation and the Cq values for each data set were calculated. Previously published data 
on what the CV values should be to show high reproducibility of the assay varies between 
publications, but generally lie in the range of 0.5% - 16%. Tables containing the CV values, 
the mean expression ratios and the standard deviations calculated for MMP1, TIMP1 and 
HGF are found in Appendix F.  It is evident from the low CV values that the qPCR assays 
had a high degree of reproducibility between the triplicate real time PCR samples. This 
high reproducibility can also be visualised using graphs (Appendix G).   
 
Depending on the initial concentration of DNA in the sample, the samples require a 
different number of cycles to reach the crossing point. Analysis uses the sample’s Cq, the 
efficiency of the reaction and the number of cycles completed to determine how much 
the DNA concentration must have increased for each sample by the end of the 
amplification. The software (Roche LightCycler® software version 4.05) then uses these 
values to calculate, compare and generate the ratios. The efficiency value for an 
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experiment is calculated by using an external standard curve or by setting the efficiency 
value (equal to two) as default in the LightCycler® software.  
 
Relative quantification can be calculated using either the 2-ΔΔCq method or the variation of 
this, the ΔCq method using a reference gene (Livak and Schmittgen, 2001). Both methods 
assume that target and reference genes are amplified with efficiencies near 100% and 
within 5% of each other. Since qPCR assumes a linear relationship between initial 
template quantity and the Cq value obtained during amplification, optimisation of the 
qPCR assay is essential for accurate and reproducible quantification. There are three 
hallmarks of an optimised qPCR assay, these are; a linear standard curve with R2 > 0.980, 
a high amplification efficiency of between 90 – 105% and consistency across replicate 
reactions (Appendix H). 
 
The ΔCq method uses a reference gene, and although simpler to perform than the Livak 
method, gives essentially the same result. This method uses the difference between the 
reference Cq and the target gene Cq for each sample. A hypothetical example of a 
calculation is: 
 
2(CP (GAPDH)-CP (target)) = Expression  
 
Patient sample: 
GAPDH CP=15.9 
Gene X CP=12 
Thus for patient gene expression, 
Expression = 2(15.9-12) = 14.9 
 
2.3. Statistical analyses 
 
Data were captured in an Excel spreadsheet and analysed using the statistical programs 
SAS (SAS Institute Inc.), STATA (StataCorp), Statistica (Statsoft Inc.) and R (R development 
core team). The non-parametric Mann-Whitney U (Wilcoxon) and one-way ANOVA tests 
were applied to compare gene expression between groups. Correlations between 
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continuous clinical variables and gene expression ratios were calculated using Spearman’s 
correlation test. Statistical significance levels were set at p<0.05.     
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Chapter 3 
 
Results 
 
3.1. Clinical description 
3.1.1. Patient demographics and clinical features 
 
The demographic, clinical and laboratory data for the patient group are summarised in 
Table 3.1. The clinical data are summarised in Appendix I. Of note is that the vast majority 
of the patients recruited for the study were female (n=14), all patients were black South 
Africans and the mean disease duration was about 2 years. It is important to note that 
one patient (patient 10) was excluded from analysis since the patient had disease 
duration of 8 years, thus only 16 patients were used in data analysis. 
 
Table 3.1. Demographic, clinical and laboratory data for the patient group 
Clinical feature Patients (n=16) 
Female: Male ratio 7:1 
Age of patient in years (mean, SD) 35.6 (10.6) 
Disease duration in months (mean, SD) 24.7 (17.2) 
Disease activity (mean, SD) 3.4 (1.7) 
MRSS (mean, SD) 22.5 (8.5) 
Involved biopsy skin score (mean, SD) 2 (0.57) 
Interstitial lung disease 3/15 (20%) 
Renal disease 2/15 (13%) 
Myositis 4 (25%) 
CRP (mean, SD) 32.5 (88.6) 
Elevated ESR 8 (50%) 
ANA positive 16 (100%) 
ATA positive 4 (25%) 
Low C4 3 (18.75%) 
 
MRSS - modified Rodnan skin score, CRP - C-reactive protein, ESR - erythrocyte sediment rate, ANA - anti-
nuclear antibodies, ATA - anti-topoisomerase 1 antibodies 
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3.1.2. Control samples 
 
Fifteen control samples were collected from the Charlotte Maxeke Johannesburg 
Academic Hospital from black adult patients undergoing reconstructive plastic surgery. 
The mean age of the control samples was 30 years. The skin samples were mainly taken 
from around the hand, wrist or forearm, with only one sample being taken from the groin 
area. The ratio of males to females was 7.5:1. Table 3.2 is a summary of the control 
samples. 
 
Table 3.2. Control sample information 
Control Age Site of skin sample Gender 
1 34 Left hand M 
2 33 Left hand M 
3 31 Skin graft – groin M 
4 58 Left hand F 
5 20 Left forearm M 
6 19 Left forearm M 
7 30 Right hand M 
8 22 Right hand M 
9 52 Left hand M 
10 31 Left hand M 
11 19 Right wrist M 
12 29 Left forearm F 
13 20 Left hand F 
14 32 Left hand M 
15 21 Right forearm M 
 
 
3.2. Gene expression 
 
Initially the ratios of gene expression were used to compare the differences in the gene 
expression between the patients and controls and between the two samples (clinically 
involved and clinically uninvolved skin) taken from each patient.  
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3.2.1. Matrix Metalloproteinase 1 
 
The differences in MMP1 gene expression are illustrated in Figure 3.1. The boxplot clearly 
shows a difference in gene expression ratio when comparing the patient group to the 
control group. MMP1 expression in the clinically uninvolved and involved skin of the SSc 
group was significantly lower than in the control group (p=0.004, for both comparisons). 
In contrast, there was no statistically significant difference in MMP1 expression between 
clinically involved and uninvolved skin (p=0.876). Figure 3.2 illustrates the expression 
levels of MMP1 in patient samples. MMP1 was calculated to have lowered expression by 
30-90% in SSc skin compared to that of the control samples.  In the majority of patients 
(n=9/16) the relative gene expression of MMP1 was higher in the uninvolved skin and in 4 
cases expression was higher in the involved skin.  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Figure 3.1.  Boxplot illustrating differences in expression ratios of MMP1 in the patient clinically uninvolved 
skin samples, patient clinically involved skin samples and control samples. 
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Figure 3.2. Means (±SEM) of normalised ratios of MMP1 to GAPDH mRNA from the triplicate runs for 
patient samples. 
 
 
3.2.2. Tissue inhibitor of metalloproteinase 1 
 
The expression ratios of TIMP1 in the controls, patient clinically uninvolved skin and 
clinically involved skin samples are illustrated in Figure 3.3. TIMP1 gene expression is very 
low in the control samples and relative to this, the patient samples have higher 
expression, especially in the clinically involved skin samples. TIMP1 expression in clinically 
involved and uninvolved SSc skin was significantly higher than the control group 
(p<0.00001, for both comparisons). A significant difference was also observed for TIMP1 
expression in the uninvolved skin compared to involved skin (p=0.05).  
 
The patient group had an overall increased expression of TIMP1 (Figure 3.4). This graph 
shows the expression levels of TIMP1 calculated according to the ΔCq method. It is clear 
that TIMP1 expression in SSc skin is expressed between 5 and 100 times more than in 
control skin.  In 11 of the 16 patients, involved skin demonstrated higher levels of 
expression than uninvolved skin. 
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Figure 3.3.  The expression ratios of TIMP1 in the different sample groups clearly show the increased 
expression in the patient samples compared to the controls.  
 
 
Figure 3.4. Means (±SEM) of normalised ratios of TIMP1 to GAPDH mRNA from the triplicate runs for 
patient samples. 
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3.2.3. Hepatocyte growth factor 
 
The relative expression ratios of HGF are shown in Figure 3.5, is clear from this boxplot 
that HGF has a higher expression in the patient samples compared to the controls. HGF 
expression in the uninvolved and involved SSc skin samples was significantly higher than 
in the control group (p=0.002 and p=0.004 respectively). In contrast, HGF expression 
reveals no significant difference between the clinically uninvolved and the involved skin 
(p=0.83). Figure 3.6 illustrates the expression levels of HGF in patient samples, and it is 
clear from this graph that this gene is expressed between 0.5 and 9 times more in SSc skin 
compared to normal skin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5.  Boxplot showing the average relative expression of HGF in the patient samples and control 
samples. 
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Figure 3.6. Means (±SEM) of normalised ratios of HGF to GAPDH mRNA from the triplicate runs for patient 
samples. 
 
 
3.3. Correlations of clinical features with gene expression profiles 
 
To calculate the associations of the clinical data with the gene expression profiles, the 
data were categorised depending on whether it was a categorical variable or continuous 
data. Continuous data (age, modified Rodnan skin score (MRSS), disease duration, 
involved skin biopsy skin score and disease activity) was analysed using the Spearman’s 
correlation coefficient (Table 3.3). The correlation plots for the two statistically significant 
relationships were generated by SAS (Figures 3.7 and 3.8). Both of these relationships 
show a positive correlation with r values greater than 0.50. Analysis of the gene 
expression data with respect to specific categorical clinical data revealed that HGF 
expression in uninvolved skin was showing a trend in correlation with renal disease (n=4, 
p=0.031). HGF in involved skin also showed a trend in significance when correlated with 
the gender of the patients (p=0.037).  
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Table 3.3. Correlations between continuous variables and gene expression 
  Involved skin Uninvolved skin 
  MMP1 TIMP1 HGF MMP1 TIMP1 HGF 
Disease 
duration 
r 
p 
-0.128 
NS 
0.306 
NS 
-0.060 
NS 
-0.375 
NS 
-0.028 
NS 
-0.034 
NS 
Age 
 
r  
p 
0.101 
NS 
-0.070 
NS 
-0.2216 
NS 
0.021 
NS 
-0.064 
NS 
0.414 
NS 
MRSS 
 
r 
p 
0.031 
NS 
0.053 
NS 
0.395 
NS 
0.479 
0.060 
-0.225 
NS 
0.500 
0.048 
Involved 
skin score 
r 
p 
-0.495 
0.061 
0.073 
NS 
0.196 
NS 
- 
- 
- 
- 
- 
- 
Disease 
activity 
r 
p 
0.292 
NS 
0.096 
NS 
0.600 
0.013 
0.276 
NS 
-0.166 
NS 
0.219 
NS 
 
 
 
 
Figure 3.7. Correlation plot between the MRSS and HGF expression ratios in uninvolved skin 
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Figure 3.8. Correlation plot showing positive relationship between SSc disease activity scores and HGF gene 
expression ratios in involved skin from SSc patients 
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Chapter 4 
Discussion 
 
Relative quantification analysis of the genes revealed that matrix metalloproteinase 1 
(MMP1) has decreased expression compared to the control samples, while both tissue 
inhibitor of metalloproteinase 1 (TIMP1) and hepatocyte growth factor (HGF) showed 
increased expression when compared to control samples. Due to their roles in the 
balance of the ECM, the results for MMP1 and TIMP1 were expected, whilst the results 
for HGF were surprising as they were not consistent with the hypothesised role the HGF 
plays in regulating the ECM. The clinical data that was collected from each patient was 
correlated to the differential expression of the genes, as the possibility that a clinical 
feature of the disease could be associated with the observed gene expression profiles, 
would be of great interest.   
 
The discussion that follows explores the implications of the findings of this study in 
greater detail. Firstly, the differential expression of the genes in SSc patients compared to 
controls is considered. Secondly, the difference in gene expression between the two 
different samples obtained from each patient, that is the involved skin sample from the 
forearm compared to the clinically uninvolved skin sample from the back, is considered. 
In the last section, an assessment is done to determine whether the differential 
expression of these genes can explain any disease manifestations in the patients.     
 
4.1. Clinical features 
 
A similar number of patients (n=16) and controls (n=15) were investigated. To be included 
into the study as a patient, the individual had to fulfil the American College of 
Rheumatology (ACR) criteria for SSc and have the diffuse subtype of the disease. The 
duration of disease at the time of biopsy was crucial for inclusion into the study. Natural 
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regression of fibrosis of the skin has been reported in patients (Distler and Distler, 2009) 
and recruiting a patient with fibrotic regression had to be avoided. Two biopsies were 
required from each patient for the study; one from clinically involved skin and the other 
from clinically uninvolved skin, which would serve as an internal control. The area chosen 
for the clinically involved biopsy was on the forearm, more specifically 4cm from the ulna 
styloid on the left arm (Whitfield et al., 2003). The skin biopsy from the back was taken 
just under the scapula. The clinically involved area from which the biopsy was taken was 
given a skin score by one of the medical doctors who completed the clinical data sheets, 
for which the average skin score was 2. The biopsy that was taken from the back is not 
clinically affected by fibrosis and as such the skin score for this biopsy in every patient was 
zero.  
 
Systemic sclerosis is considered active if a patient scores three or more on the DAS score 
(Valentini et al., 2001). In this patient group the mean disease activity score was 3.4, with 
10 patients scoring above three. This indicates that most of the patients included in this 
study had active disease at the time the biopsies were taken. The MRSS takes into 
account the skin scores for 17 areas on the body of the SSc patient. The mean MRSS in 
the patient group was 22.6, ranging from 11 to 45, placing the majority of patients 
included in this study in the severe category for skin thickness. Muscle weakness, or 
myositis is quite common in SSc patients. The frequency of visceral organ involvement, 
including lung and renal disease was 20% and 13% respectively, which was less common 
than previously reported by Tager and Tikly (1999). All patients were ANA positive whilst 
only a quarter of them were ATA positive. This however is not surprising as all the 
patients had diffuse disease. This specific ATA is associated with interstitial lung disease. 
The large proportion of patients who had an elevated ESR is similar to previous findings in 
SSc patients of African decent (Tager and Tikly, 1999).  Overall, there was nothing unusual 
about this group of patients compared to similar studies using SSc patients. 
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4.2. Differential gene expression 
 
To be included as a control, the individual had to be undergoing reconstructive surgery, 
otherwise healthy and give informed consent to donate a skin sample. Due to the nature 
of the reconstructive surgeries, there are a large number of males compared to females 
(ratio 7.5:1). Conversely, the SSc patient group had a female to male ratio of 7:1. This is 
not unusual for a study based on an autoimmune disease. In a 2007 study using 3656 SSc 
patients there was a reported gender ratio of 6:1 in favour of females (Walker et al., 
2007), while another study which included 1012 SSc patients of Italian heritage showed a 
female to male ratio of 7.8:1 (Ferri et al., 2002). The mean age of the patients recruited 
for the study was 35.6 years, 5.6 years on average more than the age of the control 
individuals. The mean disease duration for patients included in this study was 24.7 
months. 
 
In order to optimise the qPCR so that the assay was sensitive and reproducible, many 
factors were optimised. Primer concentrations started at 1µM and eventually ended at a 
usable 0.25µM, there were no spurious bands present and there was one clear, distinct 
band. The amount of cDNA added was either 500ng/µl or 1µg/µl, depending on the 
intensity of the resulting band. The number of cycles in the qPCR run was altered until a 
suitable cycle number was found. It was adjusted from 30 cycles to 45, which proved 
suitable for the production of sufficient product. Finally, 4µl of Betaine was added to two 
of the assays, this is a PCR additive which is reported to reduce the base pair composition 
dependence on DNA strand melting. 
 
4.2.1. Comparison of the gene expression levels between patient and 
control samples 
 
The three genes chosen for the study have previously been implicated in SSc and as 
mentioned previously they were chosen for their specific roles in the metabolism of the 
ECM. The matrix metalloproteinases (MMPs) are a group of endopeptidases that play a 
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pivotal role in connective tissue remodelling, especially during development, wound 
healing and other physiological processes. The endogenous inhibitors of MMPs are the 
tissue inhibitor of metalloproteinases (TIMPs), which function in controlling the activity of 
the MMPs (Iyer et al., 2007).  MMPs degrade connective tissues and TIMPs inhibit MMPs 
thereby reducing MMP activity and consequently decreasing connective tissue 
degradation. It is the balance between these molecules that controls normal ECM 
degrading activity (Huang et al., 2001).  
 
From the relative gene expression data observed, the expression of MMP1 is decreased 
which is expected in fibrotic skin, as there is an accumulation of collagen. MMP1 
expression for the patient samples compared to the controls was significantly decreased. 
A p-value of 0.004 was calculated when comparing the difference between patient 
uninvolved skin and control samples. Likewise, a p value of 0.004 was calculated for 
differences in MMP1 expression between patient involved skin and control samples.  
 
The expression of MMP1 in SSc patients, compared to controls seems to differ between 
studies. As far back as 1979, Uitto et al., found contrary to this study, that collagenase 
(MMP1) activity was increased in the fibroblasts of SSc patients. Conversely, other studies 
have reported that the activity of MMP1 is diminished (Takeda et al., 1994; Tomimura et 
al., 2008). These studies all used fibroblast cell culturing and collagen biosynthesis assays 
to determine the levels of MMP1. The number of patients varied in the studies from as 
low as 7 (Uitto et al., 1979) to 41 (Tomimura et al., 2008). Few studies stipulate the 
disease duration of the patients used and this criterion seems to be quite important as a 
recent study argued that the expression of MMP1 is not significantly different between 
late-stage disease SSc patients and controls (Zurita-Salinas et al, 2004). The rate of 
collagen degradation in SSc skin depends on the clinical stage and activity of the disease. 
Disease duration could therefore be the factor responsible for the discrepancies in the 
results of these studies. The reduction in MMP1 expression that is evident in this study 
was not unexpected; as less collagenase is produced by MMP1 the more collagen 
accumulates in the ECM resulting in fibrosis. It is evident from previous studies that cell 
culture does not always mimic the in vivo situation.  
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In agreement with previous studies (Ågren et al., 2001), TIMP1 is not highly expressed in 
normal skin and in comparison, the expression of TIMP1 was very much higher in the 
patient samples, irrespective of whether it was in clinically affected or unaffected skin 
compared to the controls. Statistically, the increases in expression of TIMP1 in both the 
involved and uninvolved skin is significant with p-values of <0.00001 for both sample 
types. Due to the role of TIMP1 in the metabolism of the ECM, the results obtained in the 
relative quantification experiments were expected. The results from the present study are 
in agreement with the study by Zurita-Salinas et al. (2004) that found TIMP1 synthesis 
was increased in the fibroblasts of SSc patients with early disease. However, they found 
no significant change of TIMP1 levels in late disease (>7 years) compared to controls. 
Meng et al. (2008) studied the expression of TIMP1 protein in the skin lesions of diffuse 
SSc patients using Immunohistochemistry. Their study found that TIMP1 protein was 
significantly increased (p<0.05) in the patient samples compared to controls.      
 
The expression of the matrix metalloproteinases and their inhibitors are transcriptionally 
regulated by a number of cytokines (TNFα), hormones, interleukins (IL-1 and IL-6) as well 
as growth factors such as TGFβ (Dhar et al., 2006). In addition, many cell-cell and cell-
matrix interactions are responsible for the expression of the MMP genes (reviewed in 
Nagase and Woessner, 1999). Inflammatory cytokines such as TNFα trigger the ceramide-
signalling pathway that drives the expression of MMP1 in human fibroblasts. Conversely 
TGFβ is known to repress MMP1 expression while inducing TIMP1 expression. This 
multifunctional growth factor has profound effects on ECM homeostasis via its ability to 
alter the balance between proteinases and their inhibitors at the level of gene expression 
(Hall et al., 2003). This key growth factor in ECM homeostasis signals via transmembrane 
receptors to intracellular mediators of the Smad family as well as through the mitogen-
activated protein kinase pathway (Dhar et al., 2006). It is well established that TGFβ plays 
an important role in the development of fibrosis and the pathogenesis of SSc (Kubo et al., 
2002; Yamane et al., 2002). It is evident that the explanation of MMP1 regulating TIMP1 
and vice versa is very simplistic. Many different cytokines, interleukins and growth factors 
are involved that constitute various pathways, all of which are involved in the expression 
of both MMP1 and TIMP1.                 
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Although comparison of gene expression data with TIMP1 and MMP1 serum levels was 
not done in this study, it is still essential that some comparison be made with previous 
studies that have been done looking at serum levels in SSc patients. In a study by Young-
Min et al. in 2001, it was found that TIMP1 serum levels were significantly raised in 
patients with diffuse SSc compared to normal controls (p=0.01), and that the increase was 
higher in patients with early disease of less than two years. The higher levels of TIMP1 
observed supports the hypothesis that there is an accumulation of the extracellular 
matrix due to a decrease in matrix degradation. The variation in the levels of TIMP1 
between early and late disease reflects the early progression of fibrosis that is observed 
clinically. The expected reduction in MMP1 serum levels was not observed as the 
difference between SSc patients and controls was not significant. Another study by 
Kikuchi et al., (1995) also showed elevated levels of TIMP1 in the serum of SSc patients. 
These patients had the diffuse form of the disease and showed an increased incidence of 
lung fibrosis and anti-topoisomerase 1. This study concluded that serum levels of TIMP1 
are a useful indicator of disease activity.    
 
Hepatocyte growth factor (HGF) is secreted by mesodermal cells and has mitogenic and 
morphogenic properties on epithelial and endothelial cells (Galimi et al., 1993). HGF could 
be important as an endocrine mediator through an epithelial-mesenchymal interaction in 
wound healing, tissue or organ regeneration and morphogenesis (Nakamura, 1991). The 
range of activity of HGF and its impact on many physiologic and pathologic processes are 
reflected by the expression of its receptor, c-met, in a wide variety of organs and cell 
types. The interaction of HGF and c-met within the immune system serves to control the 
functions of some immune cell types (Skibinski, 2003).  
 
Hepatocyte growth factor has not been widely studied in the context of SSc, although 
some studies report on the gene studied in animal models of SSc, such as tight-skin (tsk) 
mouse. HGF has been shown to have anti-apoptotic activity and has a role in suppressing 
fibrosis in the liver (Iwasaki et al., 2006). 
 
The study in lung fibroblasts of African American patients suggests that HGF expression 
might be decreased in SSc patients, but the present study shows the opposite. HGF 
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expression was increased and the highest level of expression was found in the patient 
uninvolved skin. The expression of HGF in the skin samples from the SSc patients was 
higher than the control samples. The uninvolved skin had increased expression compared 
to controls (p=0.002) and the involved skin was also significantly increased compared to 
the expression of HGF in the controls (p=0.004). Also, there was a direct correlation 
between disease activity and MRSS with respect to HGF expression in the patient 
samples. These findings suggest that HGF may play a compensatory antifibrotic role, but 
not sufficient to overcome the pro-fibrotic state.  
 
4.2.2. Gene expression comparisons between the involved and 
uninvolved skin from the SSc patients 
 
It was not only of interest to compare the expression of the genes between the patient 
and control groups, but also to assess the differences in expression of the clinically 
uninvolved and involved skin samples from the patients. The uninvolved skin sample from 
the back was used as an “internal” control for each patient and therefore it is important 
to note if any differences are observed in gene expression between these two skin 
samples from the same individual.  
 
The difference in expression of MMP1 between the uninvolved and involved skin was not 
significant (p=0.87). Conversely, TIMP1 was found to have a marginally significant 
difference (p=0.05) in expression between the uninvolved and involved skin. This study 
found that the expression of TIMP1 was greater in the clinically involved skin than in the 
clinically uninvolved skin. As there was still an increase in expression of TIMP1 in 
seemingly unaffected skin, it would seem to indicate that TIMP1 expression is generally 
up regulated in the skin of systemic sclerosis patients, but at a higher level in skin affected 
by fibrosis. 
 
HGF showed no difference in expression between the uninvolved and involved skin 
samples (p=0.83). Interestingly though, the gene was expressed at a slightly higher level in 
the uninvolved skin. It is thought that this could be the result of a compensatory 
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mechanism. As TIMP1 expression increases, leading to reduced degradation of collagen 
and the development of fibrosis, the levels of HGF increase in response to this to try and 
break down the collagen. This could account for the high expression levels of HGF in the 
uninvolved skin of the patients, which show no physical signs of fibrosis, whilst in the 
forearm the HGF levels are not as high and there is more fibrotic tissue. Studies have 
shown that HGF expression is increased in the skin fibroblasts of individuals with SSc and 
this is stimulated by growth factors such as epidermal growth factor (EGF), platelet-
derived growth factor (PDGF), basic fibroblast growth factor (bFGF) and transforming 
growth factor alpha (TGFα) (Gohda et al., 1994). Similarly the protein kinase C (PKC) 
pathway stimulates the production of HGF in skin fibroblasts (Matsunaga et al., 1994). 
 
A possible explanation for the increase witnessed in HGF expression could be that an 
increase of the expression of this gene in these patients could be the result of a 
compensatory mechanism that is induced by the decrease in MMP1 expression and the 
increase in TIMP1 expression. Perhaps the increase in TIMP1 and the decrease in MMP1 
promote the increased expression of HGF in an attempt to suppress the development or 
proliferation of fibrosis. Many studies (Nakamura et al., 2000; Cowin et al., 2001; Yoshida 
et al., 2003) have found that up-regulated HGF expression was observed after injury of 
tissues such as the lung, kidney, heart, and skin, therefore the up-regulation of HGF might 
be part of the general response to tissue damage. There are cytokines that seem to be 
responsible for this, such as interleukin-1 or 6 which activate HGF transcription 
(Michalopoulos and DeFrances, 1997). Additionally, Chmielowiec et al. (2007) showed 
that c-Met and HGF expression is induced in the hyperproliferative epithelium of skin 
wounds, indicating that receptor and ligand may act in an autocrine manner during 
wound healing.  
 
Serum levels of HGF are found to be significantly higher in SSc patients compared to 
controls (p=0.05), especially those with interstitial lung disease. Systemic sclerosis 
patients can manifest the disease with a variety of organ damage which is secondary to 
vasculitis. The elevated levels of HGF may be reflective of endothelial cell injury 
(Hashimoto et al., 2003).  Contrary to this, Hummers et al., (2009) looked at the plasma 
levels of various pro-angiogenic factors, including HGF and found that there were lower 
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levels of HGF in patients with SSc compared to healthy controls although the difference 
was not statistically significant. The latter authors postulate that an increase of pro-
angiogenic growth factors could represent an attempt at angiogenic tissue repair, and 
thus a decrease in the level of HGF is surprising due to its potent pro-angiogenic effects..  
 
The “myth” of uninvolved skin in SSc 
 
In 1991, Claman et al. did a study on skin biopsies taken from 19 SSc patients using 
immunohistochemistry. The aim of the study was to determine if there were any 
differences between clinically affected and clinically unaffected areas. They used 
antibodies to endothelial leukocyte-adherence molecule type 1 (ELAM1), which would 
detect endothelial activation, as well as antibodies to procollagen-1 (PC1) in order to 
detect newly formed, unprocessed collagen. It was found that there was an increase in 
the level of protein of ELAM1 and PC1 in SSc skin compared to the controls, there was 
however no difference between clinically affected and clinically unaffected SSc skin 
samples. They proposed that what appears to be "normal" skin in diffuse SSc is already 
pathologic, as shown by abnormal endothelial activation and procollagen production. 
From this article onwards, this phenomenon was termed the “myth of uninvolved skin in 
SSc”.  Many studies have been able to corroborate this finding, most recently studies by 
Kubo et al. (2003) and Sawaya et al. (2004). In the former study they concluded that 
uninvolved skin appears to represent an intermediate stage between normal skin and skin 
from an SSc patient. They studied the protein localisation of Fli1 in human SSc fibroblasts 
and found it to be down regulated in both the clinically affected skin samples as well as 
the clinically unaffected skin samples, although to a lesser extent in the latter. The 
Sawaya study found that clinically unaffected skin from SSc patients contained 
inflammatory cells (such as CD4+ T cells) although the number of these cells was lower 
than in affected skin. The observation that the presence of inflammatory and fibrotic 
alterations occur in clinically unaffected skin of SSc patients suggest that vascular and 
fibrotic abnormalities at the tissue level precede the clinical evidence of the disease.  
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The genes in this study show the same trend in altered gene expression compared to the 
normal in both clinically involved and uninvolved skin. For both MMP1 and HGF the 
expression levels of these genes in the uninvolved skin samples were greater than in the 
involved samples. Many studies (Nakamura et al., 2000; Cowin et al., 2001; Yoshida et al., 
2003) have found that up-regulated HGF expression was observed after injury of tissues 
such as the lung, kidney, heart, and skin, therefore the up-regulation of HGF might be 
part of the general response to tissue damage. There are cytokines that seem to be 
responsible for this, such as interleukin-1 or 6 which activate HGF transcription 
(Michalopoulos and DeFrances, 1997). Additionally, Chmielowiec et al., (2007) showed 
that c-Met and HGF expression is induced in the hyperproliferative epithelium of skin 
wounds, indicating that receptor and ligand may act in an autocrine manner during 
wound healing.   
 
4.2.3. Correlations of clinical data to the gene expression profiles  
 
Due to the small sample size used in this study, it is not possible to make many inferences 
with respect to clinical correlates. The only correlates that may have a biological 
significance are HGF gene expression in involved skin correlated with disease activity 
(r=0.60; p=0.013) and HGF gene expression in uninvolved skin correlated with the 
modified Rodnan skin scores with r=0.50 and p=0.048. The latter could be explained by 
the suggested compensatory role of HGF in response to the increase in TIMP1 expression. 
The TIMP1 protein inhibits MMP1 activity, which reduces collagen breakdown. In SSc 
patients this would be indicated with higher MRSS scores, giving a measure of increased 
thickness of the skin. From the correlation analysis it is clear that HGF is positively 
correlated with increased MRSS scores. This could explain why HGF is observed as having 
increased expression, where it was expected to have decreased expression due to it’s 
biological role in ECM degradation. With regards to the categorical data, two marginally 
significant observations were found, once again with HGF, which was found to be 
associated with gender in involved skin (p=0.037) and renal disease in uninvolved skin 
(p=0.031). Although, due to the small numbers involved these apparently significant 
associations may not be meaningful.   
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4.3.  Strengths and weaknesses of the study 
 
Due to the demographics of the individuals undergoing reconstructive plastic surgery at 
the time of control sample collection, there are a large number of males compared to 
females (ratio 7.5:1). This is opposite to the SSc patient gender ratio. This could have an 
impact on the expression profiles that were obtained for the control group. However, 
when looking at the expression ratios for the genes that were obtained for the female 
and males in the control group they are similar and this would lead me to believe that this 
is not a serious confounder in the study. It is preferable for the controls to be gender as 
well as age matched. All of the samples excluding one were collected from the arm area, 
and obtaining the skin samples from plastic surgery was the found to be the best option.  
 
The strength of this study is the number of phenotypic measurements that were done at 
the same time the biopsy was taken. The availability of complete phenotypic data gives 
context to gene expression data collected in the laboratory, and allows a better 
understanding of how the differences in gene expression may contribute to or cause the 
clinical symptoms observed in patients.  
 
Another strength of the study is the reproducibility of the relative quantification results. 
Achieving the same result in triplicate samples provides confidence that these are reliable 
and accurate results.  
 
4.4. Significance of the study – implications for clinicians and patients 
 
Clinical measurements for each patient were made at the time the skin biopsy was taken. 
This allows for accurate correlation of gene expression data to relevant clinical 
information. These comparisons between patients could lead towards a greater 
understanding about the genetic basis behind the clinical data. 
 
The data provided here are important in that they constitute the first study elucidating 
the gene expression profiles of MMP1, TIMP1 and HGF in black South African systemic 
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sclerosis patients. Comparing the expression of these genes in the South African patients 
to systemic sclerosis patients from other populations could provide insight into the 
pathogenesis of SSc and perhaps even treatment of the fibrosis. More importantly, these 
findings suggest that all three mediators of collagen metabolism are potential targets of 
drugs or therapies that could up- or down-regulate their expression.     
 
4.5. Further research 
 
Firstly the mechanism by which MMP1 and TIMP1 expression is regulated needs to be 
considered with regards to future research. As TGFβ is implicated in the regulation of 
both these genes it would be of interest to determine its differential expression in this 
same patient group. Other genes that are involved in either fibrosis or T-cell activation 
could be considered for expression studies in this patient group. In a study by Milano et 
al. (2008) they found that genes associated with fibrosis were co-expressed with markers 
of T lymphocytes and macrophages; these genes included TGFβ, FBN1 (Fibrillin 1) and the 
collagen genes. The other members of the metalloproteinase family could be 
investigated, as well as their trans-activators including AP1, PEA3, β-catenin and NFκB. 
The A PTPRC (protein tyrosine phosphatase receptor C gene) has been found to be highly 
expressed in patients with SSc. This gene is expressed on the surface of T lymphocytes.  
 
Sequencing of the exons, introns and promoter sequences of these genes would help to 
identify variants that could be responsible for differential gene expression observed. This 
method could help detect different isoforms of gene transcripts that are generated 
through alternative splicing.   
 
Following from gene expression studies it is useful to perform immunohistochemistry. 
This technique uses antibodies, which are specific to antigens on proteins to detect the 
presence, localisation (cellular and sub-cellular) and the amount of the protein in the 
sample. The technique involves skin sample sections to be placed on slides and put 
through a series of washes in buffers and incubations with the antibodies. These slides  
are analysed to see if the antibodies have bound to any protein that is present in the 
sample. It is good practice to follow qPCR experiments with immunohistochemistry, as 
 54 
 
the expression levels of mRNA within a cell are not always a true reflection of the amount 
of protein in a cell. This is due to posttranscriptional modifications or occurrences that 
lead to mRNA degradation, i.e. via RNA interference.  
 
Methylation studies can be done on the promoter sequences of MMP1, TIMP1 and HGF in 
order to assess the level of methylation at CpG sites. Pyrosequencing can be used to make 
a quantitative measurement of the amount of methylation at each CpG by providing the 
percentage of methylation at specific CpG sites in the promoter sequence. This would be 
done in order to investigate whether hyper- or hypomethylation of these genes 
promoters may in part be responsible for the gene expression patterns that have been 
found.  
 
Finally SNP DNA microarray could be used to identify new candidate genes for study. Such 
association studies would require a larger sample size to elucidate the genes that are 
exerting an influential effect in systemic sclerosis within the South African population. 
Association studies require large sample sizes in order to detect small genetic effects in 
multifactorial diseases. In order to recruit the number of patients needed, a collaborative 
effort would have to be used to collect samples throughout the country. DNA microarray 
studies are quite expensive and the vast amount of data generated could prove difficult 
to analyse, but the results obtained from such an experiment could elucidate targets that 
could be used for therapy development in order to alleviate the burden of fibrosis.  
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Chapter 5 
Conclusion 
 
This study focused on gene expression of three mediators implicated in the metabolism of 
the ECM. This is an in vivo study to examine the expression of these genes in SSc patients; 
most studies have examined either the serum or cultured fibroblasts. Not many genetic 
studies have been done in South Africa, focusing on SSc, and as such this is new 
information, relevant and specific to the South African black population of Soweto.  
 
A number of conclusions can be drawn from the work done in this study. The relative 
under expression of MMP1 and the over expression of TIMP1 reflects the pro-fibrotic 
state of scleroderma skin. The expression of both these genes in patient samples differs 
significantly from control samples. The increase in HGF expression within the patients was 
a surprising find and could play a compensatory role as a protective mechanism in 
response to the increased expression of TIMP1. However, the increase in HGF expression 
is not sufficient to overcome the pro-fibrotic state.  
 
An interesting finding in this study was that even skin that was thought to be “clinically 
uninvolved” and chosen as such for the purpose of an internal control from the back, 
showed significant alterations in gene expression compared to the expression in the 
control samples. This seems to confirm and support previous studies that have indicated 
that all skin in an SSc patient is affected by the dysregulation of collagen synthesis and 
degradation, but not all skin shows the physical signs of this internal battle for 
homeostasis. This finding could also suggest that molecular modifications in fibroblasts 
precede phenotypic changes in the skin of SSc patients.  
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APPENDIX B – INFORMATION AND CONSENT FORMS  
 
 GENETIC STUDY OF FIBROSIS IN SYSTEMIC SCLEROSIS 
(Control skin biopsy) 
Information Sheet 
Dear Sir/Madam 
 
I am Jackie Frost, a research assistant and Masters student at the National Health Laboratory Service, and I 
would like to invite you to participate in a genetics study aimed at finding out what causes fibrosis (skin 
hardening) in Systemic sclerosis. If you decide to participate in the study please note that a questionnaire 
needs to be completed, please allow 15 minutes for the questionnaire/interview to be completed. 
Participation is entirely voluntary and you will not be disadvantaged in any way if you choose not to 
participate. 
Systemic sclerosis is a complex, multi-system disease, which is known to involve the immune system, blood 
vessels and the skin. The symptom, which is most commonly identified in the disease, is the gradual 
thickening and tightening (fibrosis) of the skin. Often ulcers are found, particularly on the fingertips, which 
are slow to heal due to poor circulation. 
The aim of this study is to understand the genetic basis of the fibrosis of the skin. The knowledge gained 
could help to improve treatment for this symptom of the disease, although this will not be immediately 
available and could take several decades. 
As in any research study I need control samples. These samples will come from individuals who do not have 
systemic sclerosis or keloids. To do these studies we need to take one (1) skin sample. The skin sample from 
non-patient participants will need to be taken while the individual is undergoing skin graft surgery. A plastic 
surgeon at Chris Hani Baragwanath Hospital will be responsible for the removal of the small sample of skin 
during the course of a prearranged surgical operation. Since this will be done under a general anaesthetic 
there will be no additional pain or discomfort. 
All samples will be coded and any information obtained from this study will be kept confidential and used 
only for research purposes. Results of the study will be made available in the biomedical literature, 
The test will not involve any costs to the participant and participation is completely voluntary. You will not 
be disadvantaged in any way if you decide not to participate. 
 
Should you require any further information, please do not hesitate to contact: 
Professor Mohammed Tikly, Division of Rheumatology 
Chris Hani Baragwanath Hospital and the University of the Witwatersrand 
(011) 933-9577 
Or 
Professor Michéle Ramsay, Division of Human Genetics 
National Health Laboratory Service and the University of the Witwatersrand 
(011) 489-9214 
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GENETIC STUDY OF FIBROSIS IN SYSTEMIC SCLEROSIS 
(Patient skin biopsy) 
Information Sheet 
Dear Sir/Madam 
 
I am Jackie Frost, a research assistant and Masters student at the National Health Laboratory Service, and I 
would like to invite you to participate in a genetics study aimed at finding out what causes fibrosis (skin 
hardening) in Systemic sclerosis. If you decide to participate in the study please note that a questionnaire 
needs to be completed, please allow 15 minutes for the questionnaire/interview to be completed. 
Participation is entirely voluntary and you will not be disadvantaged in any way if you choose not to 
participate. 
Systemic sclerosis is a complex, multi-system disease, which is known to involve the immune system, blood 
vessels and the skin. The symptom, which is most commonly identified in the disease, is the gradual 
thickening and tightening (fibrosis) of the skin. Often ulcers are found, particularly on the fingertips, which 
are slow to heal due to poor circulation. 
The aim of this study is to understand the genetic basis of the fibrosis of the skin. The knowledge gained 
could help to improve treatment for this symptom of the disease, although this will not be immediately 
available and could take several decades. 
To do these studies we need to take two (2) skin biopsies. One (1) sample will be taken from the forearm 
and one (1) sample from the back. This procedure might cause some discomfort and pain. It involves the 
removal of a small piece of skin (4mm in diameter) by punch biopsy. After the procedure a steri-strip will be 
placed over the biopsy region to prevent any infections and to help the wound heal better. No stitches will 
be needed. A qualified doctor will carry out the procedure. 
All samples will be coded and any information obtained from this study will be kept confidential and used 
only for research purposes. Results will not be made available to you personally as they will need to be 
interpreted in the context of the group and their clinical value may not be apparent for several years. 
The test will not involve any costs to the participant and participation is completely voluntary. You will not 
be disadvantaged in any way if you decide not to participate. 
Should you require any further information, please do not hesitate to contact: 
 
Professor Mohammed Tikly, Division of Rheumatology 
Chris Hani Baragwanath Hospital and the University of the Witwatersrand 
(011) 933-9577 
Or 
Professor Michéle Ramsay Division of Human Genetics 
National Health Laboratory Service and the University of the Witwatersrand 
(011) 489-9214 
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GENETIC STUDY OF FIBROSIS IN SYSTEMIC SCLEROSIS 
Consent to Participate in Research Study 
 
You have been asked to participate in a research study that will look at the genetics of systemic 
sclerosis. 
You have been informed about the study by _______________________________________ 
 
Have you been informed about the procedures involved in the study? YES  NO 
 
Have you been informed that your participation in the study is entirely voluntary and you will not 
be penalised in any way it you wish not to participate?   YES  NO 
 
Are you consenting to giving a skin biopsy?    YES  NO 
 
Do you understand that results of the study will not be made available to you?  
YES  NO 
 
You may contact Professor Mohammed Tikly at (011) 933-9571 any time if you have any questions 
about the research. 
 
You may contact the Research Ethics Committee at (011) 717-1234 if you have nay questions 
about your rights as a research participant. 
 
The research study, including all information, has been described to me. I understand what my 
involvement in the study means and I voluntarily agree to participate. 
 
Full name of participant (optional):____________________________________________ 
 
 
Signature of Participant      Date 
 
 
Signature of witness      Date 
(where applicable) 
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APPENDIX C – RNA EXTRACTION PROTOCOL 
 
RNeasy Plus Micro Kit (Qiagen) 
 
 
A maximum amount of 5mg fresh or frozen tissue can generally be processed with good 
yield. As a guide, a 1.5mm cube (3.4mm3) of most animal tissues weighs 3.5–4.5mg. It is 
important to not overload the spin column with sample as this can affect the yield of 
purified RNA quite drastically. The average yield of RNA extracted using this kit was 2mg.  
 
Before starting:  
 Add 10μl β-Mecaptoethanol to 1ml RLT buffer before use, can be stored at room 
temperature for up to a month. 
 Make 80% ethanol by adding 4 volumes of 100% ethanol to RPE buffer. 
 Make 70% ethanol by adding 24ml 100% ethanol to 6ml RNAse-free water.  
 
 
Grind weighed tissue in a mortar and pestle, ensuring tissue remains frozen  
 
 
Add tissue powder to 350μl RLT buffer in a 2ml tube 
 
 
Pass lysate through needle 5 -10 times until homogenised 
 
 
Centrifuge at 18 000rcf for 3 minutes 
 
 
Remove supernatant with pipette and transfer to gDNA eliminator column 
 
 
Centrifuge for 30 seconds at 9 000rcf, save flow through 
 
 
Add 1 volume 70% ethanol, mix well by pipetting 
 
 
Transfer to RNeasy MinElute column, centrifuge for 15 seconds at 9 000rcf  
Discard flow through 
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Add 700μl RW1 buffer, centrifuge for 15 seconds at 9 000rcf 
Discard flow through 
 
 
Add 500μl RPE buffer, centrifuge for 15 seconds at 9 000rcf 
Discard flow through 
 
 
Add 500μl 80% ethanol, centrifuge for 2 minutes at 9 000rcf 
Discard collection tube and flow through 
 
 
Place column in collection tube, centrifuge for 5 minutes at 18 000rcf - lid open  
Discard collection tube and flow through 
 
 
Place column in 1.5ml tube 
 
 
Add 14μl RNAse-free water to centre of column 
 
 
Centrifuge for 1 minute at 18 000rcf to elute RNA 
 
 
RNA quantification/purity/integrity assessment 
 
 
Store the RNA at –70˚C until needed for reverse transcription 
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APPENDIX D – QPCR PRIMERS 
 
Key     Forward primer 
 Reverse primer 
 PCR product 
 
 
 
 
MMP-1>ENST00000315274 cdna:KNOWN_protein_coding 
GGGATATTGGAGCAGCAAGAGGCTGGGAAGCCATCACTTACCTTGCACTGAGAAAGAAGACAAAGGCCAGTAT
GCACAGCTTTCCTCCACTGCTGCTGCTGCTGTTCTGGGGTGTGGTGTCTCACAGCTTCCCAGCGACTCTAGAA
ACACAAGAGCAAGATGTGGACTTAGTCCAGAAATACCTGGAAAAATACTACAACCTGAAGAATGATGGGAGGC
AAGTTGAAAAGCGGAGAAATAGTGGCCCAGTGGTTGAAAAATTGAAGCAAATGCAGGAATTCTTTGGGCTGAA
AGTGACTGGGAAACCAGATGCTGAAACCCTGAAGGTGATGAAGCAGCCCAGATGTGGAGTGCCTGATGTGGCT
CAGTTTGTCCTCACTGAGGGGAACCCTCGCTGGGAGCAAACACATCTGACCTACAGGATTGAAAATTACACGC
CAGATTTGCCAAGAGCAGATGTGGACCATGCCATTGAGAAAGCCTTCCAACTCTGGAGTAATGTCACACCTCT
GACATTCACCAAGGTCTCTGAGGGTCAAGCAGACATCATGATATCTTTTGTCAGGGGAGATCATCGGGACAAC
TCTCCTTTTGATGGACCTGGAGGAAATCTTGCTCATGCTTTTCAACCAGGCCCAGGTATTGGAGGGGATGCTC
ATTTTGATGAAGATGAAAGGTGGACCAACAATTTCAGAGAGTACAACTTACATCGTGTTGCAGCTCATGAACT
CGGCCATTCTCTTGGACTCTCCCATTCTACTGATATCGGGGCTTTGATGTACCCTAGCTACACCTTCAGTGGT
GATGTTCAGCTAGCTCAGGATGACATTGATGGCATCCAAGCCATATATGGACGTTCCCAAAATCCTGTCCAGC
CCATCGGCCCACAAACCCCAAAAGCGTGTGACAGTAAGCTAACCTTTGATGCTATAACTACGATTCGGGGAGA
AGTGATGTTCTTTAAAGACAGATTCTACATGCGCACAAATCCCTTCTACCCGGAAGTTGAGCTCAATTTCATT
TCTGTTTTCTGGCCACAACTGCCAAATGGGCTTGAAGCTGCTTACGAATTTGCCGACAGAGATGAAGTCCGGT
TTTTCAAAGGGAATAAGTACTGGGCTGTTCAGGGACAGAATGTGCTACACGGATACCCCAAGGACATCTACAG
CTCCTTTGGCTTCCCTAGAACTGTGAAGCATATCGATGCTGCTCTTTCTGAGGAAAACACTGGAAAAACCTAC
TTCTTTGTTGCTAACAAATACTGGAGGTATGATGAATATAAACGATCTATGGATCCAGGTTATCCCAAAATGA
TAGCACATGACTTTCCTGGAATTGGCCACAAAGTTGATGCAGTTTTCATGAAAGATGGATTTTTCTATTTCTT
TCATGGAACAAGACAATACAAATTTGATCCTAAAACGAAGAGAATTTTGACTCTCCAGAAAGCTAATAGCTGG
TTCAACTGCAGGAAAAATTGAACATTACTAATTTGAATGGAAAACACATGGTGTGAGTCCAAAGAAGGTGTTT
TCCTGAAGAACTGTCTATTTTCTCAGTCATTTTTAACCTCTAGAGTCACTGATACACAGAATATAATCTTATT
TATACCTCAGTTTGCATATTTTTTTACTATTTAGAATGTAGCCCTTTTTGTACTGATATAATTTAGTTCCACA
AATGGTGGGTACAAAAAGTCAAGTTTGTGGCTTATGGATTCATATAGGCCAGAGTTGCAAAGATCTTTTCCAG
AGTATGCAACTCTGACGTTGATCCCAGAGAGCAGCTTCAGTGACAAACATATCCTTTCAAGACAGAAAGAGAC
AGGAGACATGAGTCTTTGCCGGAGGAAAAGCAGCTCAAGAACACATGTGCAGTCACTGGTGTCACCCTGGATA
GGCAAGGGATAACTCTTCTAACACAAAATAAGTGTTTTATGTTTGGAATAAAGTCAACCTTGTTTCTACTGTT
TT 
 
 
 
 
TIMP-1 >ENST00000218388 cdna:KNOWN_protein_coding 
TTTCGTCGGCCCGCCCCTTGGCTTCTGCACTGATGGTGGGTGGATGAGTAATGCATCCAGGAAGCCTGGAGGC
CTGTGGTTTCCGCACCCGCTGCCACCCCCGCCCCTAGCGTGGACATTTATCCTCTAGCGCTCAGGCCCTGCCG
CCATCGCCGCAGATCCAGCGCCCAGAGAGACACCAGAGAACCCACCATGGCCCCCTTTGAGCCCCTGGCTTCT
GGCATCCTGTTGTTGCTGTGGCTGATAGCCCCCAGCAGGGCCTGCACCTGTGTCCCACCCCACCCACAGACGG
CCTTCTGCAATTCCGACCTCGTCATCAGGGCCAAGTTCGTGGGGACACCAGAAGTCAACCAGACCACCTTATA
CCAGCGTTATGAGATCAAGATGACCAAGATGTATAAAGGGTTCCAAGCCTTAGGGGATGCCGCTGACATCCGG
TTCGTCTACACCCCCGCCATGGAGAGTGTCTGCGGATACTTCCACAGGTCCCACAACCGCAGCGAGGAGTTTC
TCATTGCTGGAAAACTGCAGGATGGACTCTTGCACATCACTACCTGCAGTTTTGTGGCTCCCTGGAACAGCCT
GAGCTTAGCTCAGCGCCGGGGCTTCACCAAGACCTACACTGTTGGCTGTGAGGAATGCACAGTGTTTCCCTGT
TTATCCATCCCCTGCAAACTGCAGAGTGGCACTCATTGCTTGTGGACGGACCAGCTCCTCCAAGGCTCTGAAA
AGGGCTTCCAGTCCCGTCACCTTGCCTGCCTGCCTCGGGAGCCAGGGCTGTGCACCTGGCAGTCCCTGCGGTC
CCAGATAGCCTGAATCCTGCCCGGAGTGGAAGCTGAAGCCTGCACAGTGTCCACCCTGTTCCCACTCCCATCT
TTCTTCCGGACAATGAAATAAAGAGTTACCACCCAGC 
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HGF>ENST00000222390 cdna:KNOWN_protein_coding 
AGTTCAGACCTAGATCTTTCCAGTTAATCACACAACAAACTTAGCTCATCGCAATAAAAAGCAGCTCAGAGCC
GACTGGCTCTTTTAGGCACTGACTCCGAACAGGATTCTTTCACCCAGGCATCTCCTCCAGAGGGATCCGCCAG
CCCGTCCAGCAGCACCATGTGGGTGACCAAACTCCTGCCAGCCCTGCTGCTGCAGCATGTCCTCCTGCATCTC
CTCCTGCTCCCCATCGCCATCCCCTATGCAGAGGGACAAAGGAAAAGAAGAAATACAATTCATGAATTCAAAA
AATCAGCAAAGACTACCCTAATCAAAATAGATCCAGCACTGAAGATAAAAACCAAAAAAGTGAATACTGCAGA
CCAATGTGCTAATAGATGTACTAGGAATAAAGGACTTCCATTCACTTGCAAGGCTTTTGTTTTTGATAAAGCA
AGAAAACAATGCCTCTGGTTCCCCTTCAATAGCATGTCAAGTGGAGTGAAAAAAGAATTTGGCCATGAATTTG
ACCTCTATGAAAACAAAGACTACATTAGAAACTGCATCATTGGTAAAGGACGCAGCTACAAGGGAACAGTATC
TATCACTAAGAGTGGCATCAAATGTCAGCCCTGGAGTTCCATGATACCACACGAACACAGCTTTTTGCCTTCG
AGCTATCGGGGTAAAGACCTACAGGAAAACTACTGTCGAAATCCTCGAGGGGAAGAAGGGGGACCCTGGTGTT
TCACAAGCAATCCAGAGGTACGCTACGAAGTCTGTGACATTCCTCAGTGTTCAGAAGTTGAATGCATGACCTG
CAATGGGGAGAGTTATCGAGGTCTCATGGATCATACAGAATCAGGCAAGATTTGTCAGCGCTGGGATCATCAG
ACACCACACCGGCACAAATTCTTGCCTGAAAGATATCCCGACAAGGGCTTTGATGATAATTATTGCCGCAATC
CCGATGGCCAGCCGAGGCCATGGTGCTATACTCTTGACCCTCACACCCGCTGGGAGTACTGTGCAATTAAAAC
ATGCGCTGACAATACTATGAATGACACTGATGTTCCTTTGGAAACAACTGAATGCATCCAAGGTCAAGGAGAA
GGCTACAGGGGCACTGTCAATACCATTTGGAATGGAATTCCATGTCAGCGTTGGGATTCTCAGTATCCTCACG
AGCATGACATGACTCCTGAAAATTTCAAGTGCAAGGACCTACGAGAAAATTACTGCCGAAATCCAGATGGGTC
TGAATCACCCTGGTGTTTTACCACTGATCCAAACATCCGAGTTGGCTACTGCTCCCAAATTCCAAACTGTGAT
ATGTCACATGGACAAGATTGTTATCGTGGGAATGGCAAAAATTATATGGGCAACTTATCCCAAACAAGATCTG
GACTAACATGTTCAATGTGGGACAAGAACATGGAAGACTTACATCGTCATATCTTCTGGGAACCAGATGCAAG
TAAGCTGAATGAGAATTACTGCCGAAATCCAGATGATGATGCTCATGGACCCTGGTGCTACACGGGAAATCCA
CTCATTCCTTGGGATTATTGCCCTATTTCTCGTTGTGAAGGTGATACCACACCTACAATAGTCAATTTAGACC
ATCCCGTAATATCTTGTGCCAAAACGAAACAATTGCGAGTTGTAAATGGGATTCCAACACGAACAAACATAGG
ATGGATGGTTAGTTTGAGATACAGAAATAAACATATCTGCGGAGGATCATTGATAAAGGAGAGTTGGGTTCTT
ACTGCACGACAGTGTTTCCCTTCTCGAGACTTGAAAGATTATGAAGCTTGGCTTGGAATTCATGATGTCCACG
GAAGAGGAGATGAGAAATGCAAACAGGTTCTCAATGTTTCCCAGCTGGTATATGGCCCTGAAGGATCAGATCT
GGTTTTAATGAAGCTTGCCAGGCCTGCTGTCCTGGATGATTTTGTTAGTACGATTGATTTACCTAATTATGGA
TGCACAATTCCTGAAAAGACCAGTTGCAGTGTTTATGGCTGGGGCTACACTGGATTGATCAACTATGATGGCC
TATTACGAGTGGCACATCTCTATATAATGGGAAATGAGAAATGCAGCCAGCATCATCGAGGGAAGGTGACTCT
GAATGAGTCTGAAATATGTGCTGGGGCTGAAAAGATTGGATCAGGACCATGTGAGGGGGATTATGGTGGCCCA
CTTGTTTGTGAGCAACATAAAATGAGAATGGTTCTTGGTGTCATTGTTCCTGGTCGTGGATGTGCCATTCCAA
ATCGTCCTGGTATTTTTGTCCGAGTAGCATATTATGCAAAATGGATACACAAAATTATTTTAACATATAAGGT
ACCACAGTCATAGCTGAAGTAAGTGTGTCTGAAGCACCCACCAATACAACTGTCTTTTACATGAAGATTTCAG
AGAATGTGGAATTTAAAATGTCACTTACAACAATCCTAAGACAACTACTGGAGAGTCATGTTTGTTGAAATTC
TCATTAATGTTTATGGGTGTTTTCTGTTGTTTTGTTTGTCAGTGTTATTTTGTCAATGTTGAAGTGAATTAAG
GTACATGCAAGTGTAATAACATATCTCCTGAAGATACTTGAATGGATTAAAAAAACACACAGGTATATTTGCT
GGATGATAAAGATTTCATGGGAAAAAAAATCAATTAATCTGTCTAAGCTGCTTTCTGATGTTGGTTTCTTAAT
AATGAGTAAACCACAAATTAAATGTTATTTTAACCTCACCAAAACAATTTATACCTTGTGTCCCTAAATTGTA
GCCCTATATTAAATTATATTACATTTCATATGCTATATGTTATAGTTCATTCATTTCTCTTCACCATGTATCC
TGCAATACTGGTACACGAACACACTTTTTACAAAACCACATACCCATGTACACATGCCTAG 
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APPENDIX E – QPCR Optimisation 
 
 
The series of screen shots shows the fluorescence history, melting curves and melting 
peaks of the optimisation steps for the qPCR assays.   
 
First Run 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 75 
 
Change of primer concentrations 
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Change amount of cDNA *500ng/μl+ added 
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Finally optimised 
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MMP1 was optimised with the addition of Betaine 
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APPENDIX F – DATA TABLES  
 
Table F1. Mean qPCR ratios and CV values for MMP1 assay 
Sample 
  
Mean Cq 
MMP1 
Mean Cq 
GAPDH 
Mean  
ratio 
CV 
(%) 
Sample 
(involved) 
Mean Cq 
MMP1 
Mean Cq 
GAPDH 
Mean  
ratio 
CV 
(%) 
Sample 
(uninvolved) 
Mean Cq 
MMP1 
Mean Cq 
GAPDH 
Mean  
ratio 
CV 
(%) 
Control 1 30.78 28.44 0.19 1.6 Patient 1 31.64 23.66 0.004 1.6 Patient 1 33.37 25.91 0.006 1.4 
Control 2 32.07 28.52 0.09 0.2 Patient 2 30.09 19.59 0.003 2.5 Patient 2 33.32 25.06 0.003 1.2 
Control 3 31.36 24.67 0.01 0.9 Patient 3 30.02 18.30 0.003 1.3 Patient 3 32.42 27.66 0.04 0.4 
Control 4 28.73 24.79 0.07 0.5 Patient 4 29.07 23.19 0.02 3.0 Patient 4 31.54 25.72 0.02 1.4 
Control 5 31.28 28.05 0.11 0.5 Patient 5 29.78 23.40 0.01 0.9 Patient 5 31.80 24.04 0.005 1.0 
Control 6 26.09 19.19 0.008 0.3 Patient 6 31.52 21.32 0.001 1.5 Patient 6 32.52 24.88 0.005 1.3 
Control 7 28.71 21.25 0.005 0.7 Patient 7 31.78 22.79 0.002 0.9 Patient 7 31.86 24.69 0.007 1.0 
Control 8 19.82 15.12 0.04 0.2 Patient 8 30.27 23.05 0.006 1.8 Patient 8 31.73 23.24 0.003 0.6 
Control 9 27.67 23.25 0.05 0.2 Patient 9 30.06 22.36 0.005 1.1 Patient 9 34.50 28.39 0.01 0.7 
Control 10 29.31 24.84 0.05 1.2 Patient 11 31.68 23.04 0.003 1.7 Patient 11 31.28 25.26 0.01 1.3 
Control 11 23.29 13.81 0.001 2.3 Patient 12 32.24 26.65 0.02 1.7 Patient 12 35.78 28.15 0.003 0.6 
Control 12 30.62 22.76 0.004 1.2 Patient 13 31.58 23.02 0.003 0.8 Patient 13 35.13 26.89 0.003 2.2 
Control 13 27.50 21.21 0.01 0.8 Patient 14 33.33 27.09 0.01 2.1 Patient 14 35.88 27.36 0.003 0.5 
Control 14 26.87 21.11 0.02 0.3 Patient 15 25.11 27.09 0.01 3.4 Patient 15 23.17 21.31 0.02 1.2 
Control 15 33.57 31.70 0.20 1.0 Patient 16 30.90 21.52 0.003 2.9 Patient 16 30.89 23.92 0.008 2.8 
      Patient 17 34.38 25.28 0.002 1.3 Patient 17 32.93 29.62 0.01 2.1 
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Table F2. Mean qPCR ratios and CV values for TIMP1 assay 
Sample 
  
Mean Cq 
TIMP1 
Mean Cq 
GAPDH 
Mean  
ratio 
CV 
(%) 
Sample 
(involved) 
Mean Cq 
TIMP1 
Mean Cq 
GAPDH 
Mean  
ratio 
CV 
(%) 
Sample 
(uninvolved) 
Mean Cq 
TIMP1 
Mean Cq 
GAPDH 
Mean  
ratio 
CV 
(%) 
Control 1 32.42 27.66 0.04 0.6 Patient 1 31.12 26.91 0.24 0.1 Patient 1 31.12 28.09 0.12 0.1 
Control 2 33.06 22.45 0.0006 0.8 Patient 2 29.79 22.29 0.31 0.2 Patient 2 29.79 29.43 0.78 0.3 
Control 3 34.07 22.64 0.0004 0.3 Patient 3 33.59 22.24 0.15 0.0 Patient 3 33.59 32.74 0.55 0.0 
Control 4 29.85 19.20 0.0006 0.2 Patient 4 29.31 26.03 0.44 0.0 Patient 4 29.31 28.17 0.45 0.2 
Control 5 32.24 26.65 0.02 2.4 Patient 5 30.05 26.34 0.12 0.0 Patient 5 30.05 27.02 0.12 0.2 
Control 6 29.54 17.76 0.0003 5.1 Patient 6 31.26 26.03 0.82 0.5 Patient 6 31.26 28.46 0.14 0.1 
Control 7 32.91 19.90 0.0001 0.6 Patient 7 28.86 28.93 1.56 0.3 Patient 7 28.86 28.04 0.56 0.2 
Control 8 28.47 15.76 0.0001 1.3 Patient 8 27.92 27.73 1.24 0.1 Patient 8 27.92 25.54 0.19 0.1 
Control 9 30.88 25.03 0.02 0.0 Patient 9 36.48 28.27 1.69 0.7 Patient 9 36.48 34.62 0.27 1.7 
Control 10 33.06 21.44 0.0003 2.4 Patient 11 25.95 28.31 1.22 0.1 Patient 11 25.95 24.79 0.45 0.6 
Control 11 30.53 18.95 0.0003 1.2 Patient 12 36.15 30.28 1.33 0.0 Patient 12 36.15 34.42 0.30 0.2 
Control 12 34.61 23.96 0.0006 1.3 Patient 13 32.97 26.10 0.32 0.2 Patient 13 32.97 28.19 0.07 0.2 
Control 13 31.40 30.10 0.04 0.1 Patient 14 32.92 31.73 0.15 0.2 Patient 14 32.92 28.62 0.05 0.1 
Control 14 32.63 20.35 0.0002 1.4 Patient 15 27.72 25.15 0.03 0.3 Patient 15 27.72 21.18 0.01 0.1 
Control 15 33.25 21.95 0.0004 1.5 Patient 16 36.48 29.53 0.02 0.1 Patient 16 36.48 30.64 0.02 0.1 
       Patient 17 32.92 25.13 0.06 0.1 Patient 17 32.92 28.62 0.05 0.2 
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Table F3. Mean qPCR ratios and CV values for HGF assay 
Sample 
  
Mean Cq 
HGF 
Mean Cq 
GAPDH 
Mean  
ratio 
CV 
(%) 
Sample 
(involved) 
Mean Cq 
HGF 
Mean Cq 
GAPDH 
Mean  
ratio 
CV 
(%) 
Sample 
(uninvolved) 
Mean Cq 
HGF 
Mean Cq 
GAPDH 
Mean  
ratio 
CV 
(%) 
Control 1 32.21 31.66 0.07 0.5 Patient 1 29.79 24.95 0.04 0.5 Patient 1 33.85 26.33 0.005 0.4 
Control 2 34.82 25.19 0.001 0.1 Patient 2 28.72 20.64 0.004 0.9 Patient 2 33.46 25.23 0.003 2.1 
Control 3 32.06 25.28 0.009 0.2 Patient 3 29.82 22.53 0.006 2.2 Patient 3 33.33 27.61 0.02 0.6 
Control 4 31.59 19.54 0.0003 0.3 Patient 4 30.01 25.19 0.03 0.8 Patient 4 32.38 26.99 0.03 3.3 
Control 5 35.38 27.96 0.007 0.6 Patient 5 28.25 23.97 0.05 0.7 Patient 5 30.38 24.02 0.01 1.1 
Control 6 30.47 21.06 0.002 4.9 Patient 6 30.65 24.16 0.01 1 Patient 6 33.43 25.58 0.005 2.1 
Control 7 31.39 23.19 0.003 1.1 Patient 7 31.13 26.19 0.03 1 Patient 7 31.82 26.22 0.02 2.6 
Control 8 27.79 14.88 0.0001 4.7 Patient 8 30.88 25.03 0.02 1.3 Patient 8 32.65 23.74 0.002 1.2 
Control 9 33.93 23.36 0.0007 1.3 Patient 9 29.44 26.46 0.06 1.6 Patient 9 32.60 28.71 0.07 3.8 
Control 10 31.11 25.20 0.02 0.2 Patient 11 29.90 25.09 0.04 0.9 Patient 11 31.50 26.54 0.03 1.7 
Control 11 30.43 15.60 0.0003 1.9 Patient 12 27.68 20.55 0.002 1 Patient 12 32.79 27.34 0.03 0.9 
Control 12 31.27 21.46 0.001 1.2 Patient 13 31.76 29.15 0.004 0.6 Patient 13 30.67 27.20 0.09 0.3 
Control 13 30.82 19.15 0.0003 0.7 Patient 14 28.79 26.99 0.007 0.5 Patient 14 32.82 27.57 0.03 0.7 
Control 14 32.35 21.60 0.0006 0.9 Patient 15 28.15 24.68 0.02 0.5 Patient 15 28.77 22.61 0.01 0.1 
Control 15 34.26 31.18 0.11 0.2 Patient 16 27.41 25.11 0.006 0.8 Patient 16 28.48 24.29 0.06 2.8 
       Patient 17 33.12 27.57 0.02 0.2 Patient 17 31.40 30.10 0.04 1 
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APPENDIX G – REPRODUCIBILITY GRAPHS 
 
Graphs showing reproducibility of the qPCR assays; a) control samples and b) patient clinically uninvolved 
and involved skin.  
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APPENDIX H – QPCR AMPLIFICATION EFFICIENCY  
 
 
y = -3.40x + 31.66
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E = 10(–1/slope) x 100% 
E = 96.84% 
Amplification factor = 1.97 
 
y = -3.45x + 30.794
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E = 10(–1/slope) x 100% 
E = 94.92% 
Amplification factor = 1.95 
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y = -3.33x + 26.542
R2 = 0.9965
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E = 10(–1/slope) x 100% 
E = 99.66% 
Amplification factor = 2 
 
 
y = -3.48x + 34.471
R2 = 0.9946
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E = 10(–1/slope) x 100% 
E = 94.80% 
Amplification factor = 1.94 
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APPENDIX I – SUMMARISED CLINICAL DATA FOR EACH PATIENT 
Table I. Clinical features of systemic sclerosis patients 
Patient Age/Sex 
Duration 
months 
ACR/diffuse 
disease 
Skin score 
(0-51) 
Involved/un- 
Involved skin score 
Disease 
activity 
ESR 
(>30) CRP 
Lung disease/ 
Renal disease Myositis 
ANA/ ATA/ 
Low C4 
1 25/F 24 Y/Y 26 2/0 2 N 7.4 -/- Y +/-/- 
2 34/F 23 Y/Y 11 2/0 1.5 N 14.3 -/- N +/-/+ 
3 27/F 12 Y/Y 20 2/0 1.5 N 7.2 -/- N +/-/- 
4 50/F 22 Y/Y 21 1/0 6 Y <1 -/- N +/+/- 
5 26/F 2 Y/Y 16 2/0 4 Y 339.5 No data Y +/-/+ 
6 23/F 24 Y/Y 16 2/0 3.5 Y 11.1 -/- N +/+/- 
7 48/F 25 Y/Y 18 3/0 3.5 N 7.5 +/- N +/+/+ 
8 37/F 49 Y/Y 18 1/0 2.5 Y 1.3 -/- N +/+/- 
9 28/F 32 Y/Y 36 3/0 6 Y 9.3 -/- Y +/-/- 
11 28/F 15 Y/Y 28 2/0 4 N 32.8 -/- N +/-/- 
12 39/M 17 Y/Y 18 2/0 1 N 6 -/- N +/-/- 
13 28/M 22 Y/Y 26 2/0 3.5 N No data +/+ N +/-/- 
14 48/F 35 Y/Y 20 2/0 6 N 8.3 +/- Y +/-/- 
15 28/F 3 Y/Y 26 2/0 5 Y 8.9  -/- N +/-/- 
16 50/F 74 Y/Y 16 2/0 1 N 5.9 -/- N +/-/- 
17 52/F 14 Y/Y 45 3/0 3.5 Y 5.7 -/+ N +/-/- 
 
 
 
 
 
 
